All original Yeast-two-hybrid files are available via the Open Science Framework (<https://osf.io/ef74w/>). All original Western blot files are available via the Open Science Framework (<https://osf.io/ef74w/>). All other relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

Wnt/ß-catenin signalling is crucial for embryonic development and tissue homeostasis in all multicellular animals. In mammals, it is first required for induction of the primitive streak at the onset of gastrulation \[[@pone.0227435.ref001]\]. It continues to help control cell proliferation and differentiation at different anatomical sites during all subsequent steps of tissue morphogenesis and throughout postnatal life. At the molecular level, Wnt/ß-catenin signalling promotes the formation of CTNNB1/TCF complexes, in which ß-catenin (CTNNB1) functions as a co-activator for transcription factors of the TCF/LEF family to modulate gene expression in a tissue-specific fashion.

The dynamic expression of 19 different WNT proteins results in a complex signalling landscape \[[@pone.0227435.ref002]\]. Secreted WNT proteins can interact with a variety of receptors and co-receptors at the cell surface, including FZD, LRP, RYK and ROR \[[@pone.0227435.ref003]--[@pone.0227435.ref006]\]. Different combinations result in alternative, context-dependent biochemical responses, with Wnt/ß-catenin signalling being just one possible outcome. How these specific cellular responses are induced, both upstream at the level of ligand and receptor binding and downstream at the level of intracellular signal transduction, remains an area of active investigation.

Under physiological conditions, activity of the Wnt/ß-catenin pathway is tightly controlled. A so-called 'destruction complex', containing AXIN1, APC, CSNK1 and GSK3, continuously binds and phosphorylates free CTNNB1. Because phosphorylated CTNNB1 is rapidly degraded by the proteasome, this ensures that low levels of cytoplasmic and nuclear CTNNB1 are maintained in the absence of a WNT signal. When WNT proteins engage FZD/LRP at the cell surface, the destruction complex is inactivated, resulting in an increase in the nucleocytoplasmic levels of CTNNB1 and the concomitant induction of CTNNB1/TCF transcriptional activity \[[@pone.0227435.ref007]--[@pone.0227435.ref010]\].

FRAT/GBP proteins are potent activators of CTNNB1/TCF signalling independent from WNT/FZD activity due to their capacity to bind GSK3 \[[@pone.0227435.ref011]--[@pone.0227435.ref013]\]. FRAT1 and AXIN1 compete for the same binding site on GSK3B \[[@pone.0227435.ref014]\]. Since the interaction between GSK3 and AXIN1 has been estimated to enhance the phosphorylation of CTNNB1 more than 20,000-fold \[[@pone.0227435.ref015]\], sequestration of GSK3 by FRAT thus increases CTNNB1/TCF signalling.

First identified as an oncogene in murine T-cell lymphoma progression \[[@pone.0227435.ref016]\], FRAT1 overexpression indeed correlates with the accumulation of CTNNB1 in a variety of human cancers \[[@pone.0227435.ref017]--[@pone.0227435.ref021]\]. The *Xenopus* FRAT homologue, GBP, is critically required for dorsoventral axis formation as part of the maternal Wnt pathway \[[@pone.0227435.ref013]\]. However, FRAT function is dispensable for Wnt/ß-catenin signalling in mice \[[@pone.0227435.ref022]\], indicating that FRAT is a modulator, rather than a core component of the Wnt/ß-catenin pathway in mammals. Moreover, the oncogenic activities of FRAT in lymphomagenesis may at least partially be GSK3 independent \[[@pone.0227435.ref023],[@pone.0227435.ref024]\]. To date, the precise role and regulation of FRAT1, and its close homologue FRAT2, remain to be resolved.

Here we identify TMEM98 as a novel FRAT2-binding protein. We show that TMEM98 inhibits FRAT-induced CTNNB1/TCF signalling by reducing FRAT protein levels. We also demonstrate that TMEM98 traffics between multiple endosomal and membrane compartments. Together, these findings add a new layer of regulation for Wnt/ß-catenin signalling and provide a potential molecular mechanism for the activities of TMEM98, mutations in which have been linked to autosomal dominant nanophthalmos \[[@pone.0227435.ref025],[@pone.0227435.ref026]\].

Results {#sec002}
=======

TMEM98 is a novel FRAT2-binding protein {#sec003}
---------------------------------------

To shed more light on FRAT protein function, we set out to identify new FRAT interactors. Focusing our efforts on FRAT2, we performed a yeast-two-hybrid assay using both full-length FRAT2 and an N-terminal deletion mutant containing the GSK3-binding site (FRAT2ΔN) as a bait. While we did not pick up GSK3 or any other known WNT pathway components in this screen, we did identify a number of putative novel FRAT2 binding proteins (Tables [1](#pone.0227435.t001){ref-type="table"} and [2](#pone.0227435.t002){ref-type="table"}). One candidate, an unknown protein encoded by both the *DKFZp564K1964* and *ETVV536* transcripts, was picked up with high confidence in both the FRAT2 full-length and the FRAT2ΔN screen. We therefore decided to characterize this interaction in more detail.

10.1371/journal.pone.0227435.t001

###### Novel FRAT2-binding proteins identified in a yeast-two-hybrid screen with full-length FRAT2 as bait.

![](pone.0227435.t001){#pone.0227435.t001g}

  Protein   Clone Name                                                                                                    \# clones   PBS score   Confidence
  --------- ------------------------------------------------------------------------------------------------------------- ----------- ----------- ------------
  TMEM98    hDKFZP564K1964 \[gi\|7661615\|ref\|NM_015544.1\| Homo sapiens DKFZP564K1964 protein (DKFZP564K1964), mRNA\]   5           A           Very high
  CEP170    hkab; hKIAA0470 \[gi\|7662141\|ref\|NM_014812.1\| Homo sapiens KIAA0470 gene product (KIAA0470), mRNA\]       3           E           Low

Putative interactors are listed in order of decreasing confidence (reflected in the Predicted Biological Score (PBS)).

10.1371/journal.pone.0227435.t002

###### Novel FRAT2-binding proteins identified in a yeast-two-hybrid screen with FRAT2ΔN as bait.

![](pone.0227435.t002){#pone.0227435.t002g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein    Clone Name                                                                                                                                                                          \# clones   PBS score   Confidence
  ---------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ----------- ------------
  CEP170     hKAB; hKIAA0470;\                                                                                                                                                                   15          A           Very High
             \[prey427374---Human KAB\]                                                                                                                                                                                  

  MRFAP1L1   hPP784; \[gi\|44921607\|ref\|NM_203462.1\| Homo sapiens PP784 protein (PP784), transcript variant 2, mRNA\]                                                                         11          A           Very High

  FTSJ3      hFTSJ3; \[prey427205---Human FTSJ3\]                                                                                                                                                3           B           High

  RALGAPA1   hGARNL1; \[gi\|51230411\|ref\|NM_194301.2\| Homo sapiens GTPase activating Rap/RanGAP domain-like 1 (GARNL1), transcript variant 2, mRNA\]                                          8           B           High

  TMEM98     hETVV536; \[gi\|37182267\|gb\|AY358573.1\| Homo sapiens clone DNA56050 ETVV536 (UNQ536) mRNA, complete cds\]                                                                        5           B           High

  RB1CC1     hRB1CC1; \[gi\|41350194\|ref\|NM_014781.3\| Homo sapiens RB1-inducible coiled-coil 1 (RB1CC1), mRNA\]                                                                               2           D           Moderate

  SACS       hSACS; \[gi\|38230497\|ref\|NM_014363.3\| Homo sapiens spastic ataxia of Charlevoix-Saguenay (sacsin) (SACS), mRNA\]                                                                4           D           Moderate

  SEC24C     hSEC24C; \[gi\|38373668\|ref\|NM_004922.2\| Homo sapiens SEC24 related gene family, member C (S. cerevisiae) (SEC24C), transcript variant 1, mRNA\]                                 2           D           Moderate

  CTNNA2     hCTNNA2; \[prey427324---Human CTNNA2\]                                                                                                                                              2           D           Moderate

  DNM1       hDNM1; hdynamin; \[gi\|181848\|gb\|L07807.1\|HUMDYNA Human dynamin mRNA, alternative exons and complete cds\]                                                                       4           D           Moderate

  FBXO30     hFBXO30; \[gi\|54112383\|ref\|NM_032145.4\| Homo sapiens F-box protein 30 (FBXO30), mRNA\]                                                                                          3           D           Moderate

  ATRX       hATRX; \[gi\|20336208\|ref\|NM_000489.2\| Homo sapiens alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) (ATRX), transcript variant 1, mRNA\]   6           E           Low

  UBAC1      hGDBR1; hGBDR1; hUBADC1; \[gi\|7705380\|ref\|NM_016172.1\| Homo sapiens ubiquitin associated domain containing 1 (UBADC1), mRNA\]                                                   2           E           Low
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Putative interactors are listed in order of decreasing confidence (reflected in the PBS score).

Since performing these initial studies, the 226 amino-acid FRAT2-binding protein encoded by the *DFKZp564K1964* and *ETVV536* transcripts has officially become annotated as TMEM98, a putative transmembrane protein of unknown function. Similar to FRAT, TMEM98 is highly conserved among vertebrate species, but not present in invertebrates ([S1 Fig](#pone.0227435.s001){ref-type="supplementary-material"}). The human and mouse homologues are more than 98% identical at the amino acid level, while the human and chick homologues are most divergent, with 73% of amino acid identity ([S1 Fig](#pone.0227435.s001){ref-type="supplementary-material"}).

Based on the sequence of the *TMEM98* clones that were isolated in the original yeast-two-hybrid screen, the FRAT2 binding domain of TMEM98 is located in the C-terminal half of the protein, with the longest clone spanning amino acids 66--226 and the shortest clone spanning amino acids 109--216 ([S2 Fig](#pone.0227435.s002){ref-type="supplementary-material"}). The fact that TMEM98 was identified in both the full-length FRAT2 and the FRAT2ΔN screen suggests that the TMEM98 binding domain of FRAT2 also resides in the C-terminus. By co-expressing myc-tagged FRAT2 and FLAG-tagged TMEM98 plasmid constructs, we were able to confirm binding of FRAT2 and full length TMEM98, but not an N-terminal deletion mutant lacking amino acids 1--34 (TMEM98ΔN), by co-immunoprecipitation from HEK293 cell lysates ([Fig 1A and 1B](#pone.0227435.g001){ref-type="fig"}). Western blot analysis revealed TMEM98ΔN to be unstable. Unlike full-length TMEM98, the deletion mutant can only be detected in the presence of the proteasome inhibitor MG132 ([Fig 1C](#pone.0227435.g001){ref-type="fig"}). Of note, co-expression of FRAT2 also stabilizes TMEM98ΔN ([Fig 1B](#pone.0227435.g001){ref-type="fig"}), suggesting that the two do interact, at least transiently, as a result of which at least some of the TMEM98ΔN escapes degradation.

![TMEM98 binds FRAT2.\
(A) Schematic showing FLAG-tagged expression constructs of full-length TMEM98 (amino acids 1--226) and an N-terminal deletion mutant (amino acids 34--226, TMEM98ΔN). Topology prediction programs indicate a potential signal sequence or N-terminal transmembrane region (TM1) and a putative second transmembrane region (TM2) around position 161--172. (B) Western blot showing co-immunoprecipitation of myc-FRAT2 with full-length TMEM98-FLAG in lysates from transiently transfected HEK239T cells. Asterisks indicate cross reactivity of the secondary antibody with the heavy and light chain of the anti-FLAG antibody used to pull down TMEM98-FLAG. The deletion mutant TMEM98ΔN-FLAG is not pulled down under the conditions used. However, it can be detected in protein lysates when myc-FRAT2 is co-transfected. Size markers are indicated. (C) Western blot showing a stabilizing effect of the proteasome inhibitor MG132 on TMEM98ΔN-FLAG protein levels following transient transfection of the indicated constructs in HEK293T cells. Endogenous GSK3ß was used as a loading control. Size markers are indicated.](pone.0227435.g001){#pone.0227435.g001}

TMEM98 membrane localization and topology {#sec004}
-----------------------------------------

Because TMEM98 did not contain any known motifs or functional sites, we performed hydrophobicity analyses and subcellular localization predictions. All five secondary structure prediction algorithms used (HMMTOP; Phobius; TMHMM; TMpred; DAS-TMfilter) unanimously predict TMEM98 to have an N-terminal transmembrane domain spanning residues 6--25 ([Table 3](#pone.0227435.t003){ref-type="table"}, [S1 Fig](#pone.0227435.s001){ref-type="supplementary-material"}). A TMEM98-GFP fusion protein indeed localizes to the plasma membrane ([Fig 2A](#pone.0227435.g002){ref-type="fig"}), in addition to showing more prominent localization to the Golgi and intracellular vesicles ([Fig 2A and 2B](#pone.0227435.g002){ref-type="fig"}). Forward trafficking was inhibited by treatment of the cells with Brefeldin A, a reversible inhibitor of protein transport from the ER to the Golgi ([Fig 2C](#pone.0227435.g002){ref-type="fig"}), suggesting that TMEM98 is transported to the plasma membrane via the classical, secretory pathway.

![TMEM98 is a transmembrane protein with an N-terminal transmembrane domain and an extracellular C-terminus.\
(A) Live-cell confocal microscopy image of HeLa cells co-transfected with TMEM98-sGFP2 (left) and LCK-mCherry (which localizes to the plasma membrane, middle), showing co-localization of the two proteins in the membrane (right, overlay). The yellow and blue arrowheads indicate prominent localization of TMEM98, but not LCK, to large vesicular structures (yellow) and the Golgi (blue). Graph depicts the intensity plot profile of the fluorescent signal for TMEM98-sGFP2 and LCK-mCherry along the line drawn in the panels on the left. Yellow and blue arrowheads serve as points of reference. Asterisks indicate the plasma membrane. (B) Confocal microscopy image of methanol-fixed HeLa cells transiently transfected with TMEM98-AcGFP (left). Staining with anti-Golgin97 antibody (middle) shows that TMEM98-AcGFP localizes to the Golgi apparatus (right, overlay). Nuclei are stained with DAPI and are shown in blue. Note that membrane localization is less prominent in this case because the Golgi is located in a different, more apical focal plane. (C) Pseudo-coloured confocal microscopy images of fixed HEK293A cells transiently transfected with TMEM98-AcGFP, showing that TMEM98 travels to the plasma membrane via the secretory route. Cells were treated with Brefeldin A for 4 hours to block forward trafficking through the Golgi, after which they were released. Cells were fixed at 0, 30, 60 and 180 minutes following release. Representative examples are shown. After 60 minutes, TMEM98-AcGFP reappears in the Golgi and after 180 minutes some signal can again be detected at the plasma membrane (arrowheads). (D) Pseudo-coloured confocal microscopy images of fixed HEK293A cells transiently transfected with TMEM98-AcGFP (left) or TMEM98ΔN-AcGFP, a deletion mutant lacking the first 34 amino acids (right). TMEM98ΔN-AcGFP localizes throughout the cell at much lower levels than the full length fusion protein (individual cells are indicated by arrowheads, some non-transfected surrounding cells are indicated by an asterisk positioned in the nucleus). (E) Pseudo-coloured confocal microscopy images of fixed 293A cells transiently transfected with a fusion construct in which AcGFP was tagged with the first 34 amino acids of TMEM98 (TM1-AcGFP, left), showing that TM1 is sufficient for targeting to the ER. In contrast, an untagged, free-floating fluorescent protein diffuses throughout the cytoplasm and nucleus (AcGFP, right). (F) Schematic depicting the orientation of a single-pass type I (left) or type II (right) transmembrane protein. (G) Western blot showing doxycycline dependent induction of TMEM98-FLAG in HEK293T cells stably transfected with *tetO-TMEM98-FLAG* and *CMV-rtTA3*. Size markers are indicated. (H) FACS analysis of the cells described in (G) in the absence (blue) and presence (red) of doxycycline (DOX) to induce TMEM98-FLAG expression. Following staining with an anti-FLAG antibody, TMEM98-FLAG can be detected in both unfixed, unpermeablized cells (left) and in fixed, permeabilized cells (right). The higher signal obtained in fixed, permeabilized cells likely reflects the large pool of TMEM98-FLAG present in the Golgi and intracellular vesicles, which is not detected by only staining the plasma membrane pool with an extracellularly exposed C-terminus.](pone.0227435.g002){#pone.0227435.g002}

10.1371/journal.pone.0227435.t003

###### Secondary structure prediction of TMEM98.

![](pone.0227435.t003){#pone.0227435.t003g}

  Algorithm        TM regions       Topology                                     Other
  ---------------- ---------------- -------------------------------------------- ----------------------------------------------------------------------------
  *DAS-TMfilter*   6--25 (TM1)      n.p.                                         Potential signal peptide in TM1
                   161--172 (TM2)                                                
  *HMMTOP*         9--32 (TM1)      N-terminus out; Single pass type I protein   
  *PHOBIUS*        6--27 (TM1)      N-terminus out; Single pass type I protein   Non-significant signal peptide in TM1; Non-significant TM2 around 156--173
  *TMHMM*          4--26 (TM1)      N-terminus out; Single pass type I protein   Potential N-terminal signal peptide
  *TMpred*         4--26 (TM1)      N-terminus out; Single pass type I protein   Non-significant TM2 around 157--176

Predictions are based on the human TMEM98 primary amino acid sequence. Putative transmembrane regions are numbered according to their amino acid position. TM = transmembrane, n.p. = not predicted.

To test the requirement of the TMEM98 N-terminus for targeting, we compared the localization of TMEM98 and TMEM98ΔN. Whereas full-length TMEM98 localizes to the Golgi and the plasma membrane, TMEM98ΔN shows diffuse expression throughout the cytoplasm at much lower levels ([Fig 2D](#pone.0227435.g002){ref-type="fig"}), in agreement with its rapid turnover by the proteasome ([Fig 1C](#pone.0227435.g001){ref-type="fig"}). Further support for a role of the TMEM98 N-terminus in subcellular targeting comes from the fact that an N-terminally tagged version of TMEM98 (GFP-ORF) becomes trapped in the ER, in contrast to a C-terminal fusion protein (ORF-GFP) that properly traffics to the Golgi and the cell membrane ([S3 Fig](#pone.0227435.s003){ref-type="supplementary-material"}, \[[@pone.0227435.ref027]--[@pone.0227435.ref029]\]). Finally, the first 34 amino acids by themselves (TM1) are sufficient to target a fluorescent protein to the ER ([Fig 2E](#pone.0227435.g002){ref-type="fig"}). Together, these results demonstrate that the N-terminus of TMEM98 is both necessary and sufficient for targeting to the secretory pathway.

Although these results establish that TMEM98 contains an N-terminal transmembrane domain, prediction algorithms and the published literature do not agree on its exact topology or subcellular localization. Two out of five secondary structure prediction algorithms propose the presence of a putative N-terminal signal peptide (TMHMM; DAS-TMfilter, [Table 3](#pone.0227435.t003){ref-type="table"}), but only one signal peptide prediction algorithm also estimates this sequence to be cleaved (PrediSi, [Table 4](#pone.0227435.t004){ref-type="table"}). Four out of five algorithms (HMMTOP; Phobius; TMHMM; TMpred) predict TMEM98 to be a single pass type I protein ([Table 3](#pone.0227435.t003){ref-type="table"}). In contrast, an experimental study reported TMEM98 to be a single pass type II protein, which was also found to be secreted in its full-length form \[[@pone.0227435.ref030]\]. To resolve this apparent discrepancy, we first determined whether the C-terminus of TMEM98 is located extracellularly or intracellularly ([Fig 2F](#pone.0227435.g002){ref-type="fig"}). To this end, we generated a stable cell line expressing a doxycycline inducible TMEM98-FLAG protein ([Fig 2G](#pone.0227435.g002){ref-type="fig"}) and stained these cells with an anti-FLAG antibody under both unpermeabilized and permeabilized conditions. Subsequent FACS analysis revealed a clear signal for doxycycline-induced cells in both conditions ([Fig 2H](#pone.0227435.g002){ref-type="fig"}, [S4 Fig](#pone.0227435.s004){ref-type="supplementary-material"}), thus confirming that the TMEM98 C-terminus is, at least partially, located on the extracellular side of the plasma membrane.

10.1371/journal.pone.0227435.t004

###### Subcellular localization predictions of TMEM98.

![](pone.0227435.t004){#pone.0227435.t004g}

  Algorithm      Cleavage position   Subcellular localization   Score/Confidence
  -------------- ------------------- -------------------------- ------------------
  *PrediSi*      29                  secreted                   0.6445
  *WOLF PSORT*   n.p.                Extracellular              21
                                     ER                         5
                                     Plasma membrane            3
  *SherLoc2*     n.p.                ER                         0.57
                                     Golgi                      0.25
                                     Extracellular              0.07
                                     Plasma membrane            0.05
                                     Lysosomal                  0.05
                                     Cytoplasmic                0.01
                                     Mitochondrial              0.0
                                     Nuclear                    0.0
                                     Peroxisomal                0.0

Predictions are based on the human TMEM98 primary amino acid sequence. Putative cleavage sites are numbered according to their amino acid position. n.p. = not predicted.

TMEM98 is a negative regulator of Wnt/ß-catenin signalling {#sec005}
----------------------------------------------------------

Having confirmed that FRAT2 and TMEM98 physically interact ([Fig 1](#pone.0227435.g001){ref-type="fig"}), we next investigated whether TMEM98 altered FRAT2 activity. To this end, we measured FRAT2 induced CTNNB1/TCF signalling in HEK293T cells using the well-known TOPFLASH luciferase reporter assay. Co-transfection experiments showed that TMEM98 reduced the level of CTNNB1/TCF signalling induced by FRAT2 ([Fig 3A](#pone.0227435.g003){ref-type="fig"}).

![TMEM98 inhibits FRAT-induced CTNNB1/TCF signalling.\
(A) Dual luciferase reporter assay in transiently transfected HEK293T cells to quantify the levels of CTNNB1/TCF signalling. Transfecting increasing amounts of Tmem98-FLAG cDNA with a constant amount of myc-Frat2 cDNA inhibits FRAT2 induced TCF/LEF (TOPFLASH) reporter activity. Graph depicts data from n = 4--8 independent experiments for each condition, with each data point representing the average of three technical replicates. Boxes depict the spread of the data. Horizontal bars depict the median value. TOPFLASH luciferase values are normalized to CMV-Renilla, which was included as a transfection control. For each individual experiment the baseline TOPFLASH luciferase reporter activity in HEK293T cells transfected with empty vector (instead of myc-Frat2) was set to 1. Statistically significant differences (one-way ANOVA, Tukey's multiple comparisons test) are indicated with asterisks: \*\*\*\*: P ≤ 0.0001, \*\*\*: P ≤ 0.001, \*\*: P ≤ 0.01, \*: P ≤ 0.05. (B) Same as in (A), but this time showing the effect of full-length TMEM98-Flag on myc-FRAT1 as well as myc-FRAT2. Note that FRAT1 is a more potent activator of CTNNB1/TCF signalling than FRAT2. Graph depicts data from n = 6--7 independent experiments, with each data point representing the average of three technical replicates. Boxes depict the spread of the data. Horizontal bars depict the median value. Only statistically significant differences (one-way ANOVA, Tukey's multiple comparisons test) are indicated with asterisks: \*\*\*\*: P ≤ 0.0001, \*\*\*: P ≤ 0.001, \*\*: P ≤ 0.01, \*: P ≤ 0.05.](pone.0227435.g003){#pone.0227435.g003}

We next asked whether the observed effect was specific for FRAT2. To this end, we measured the effect of TMEM98 on the induction of CTNNB1/TCF signalling by both myc-FRAT1 and myc-FRAT2 ([Fig 3B](#pone.0227435.g003){ref-type="fig"}). Full-length TMEM98 almost reverted FRAT2-induced TOPFLASH reporter activity back to baseline (from 4.5 ± 1.8 to 1.1 ± 0.48 fold induction; mean ± standard deviation). When equal amounts of *FRAT1* plasmid DNA were transfected, full-length TMEM98 reduced FRAT1-mediated TOPFLASH reporter activity to a similar extent (from 9.9 ± 6.1 to 3.3 ± 2.3 fold induction), equating to a 66% reduction for FRAT1 and a 76% reduction for FRAT2 on average. Indeed, myc-FRAT1 can also be co-immunoprecipitated with full length TMEM98-FLAG upon overexpression in HEK293T cells ([S5 Fig](#pone.0227435.s005){ref-type="supplementary-material"}). Thus, TMEM98 is capable of interacting with both FRAT homologues and blocks FRAT activity.

TMEM98 reduces FRAT2 protein levels {#sec006}
-----------------------------------

To determine how TMEM98 inhibits the signalling activities of FRAT2, we tested whether TMEM98 affected FRAT2 protein levels. To this end, we co-transfected a constant amount of *myc-Frat2* plasmid DNA with increasing amounts of *Tmem98* in HEK293T cells. Quantitative Western blot analysis revealed a variable, but consistent reduction in FRAT2 protein levels in the presence of full length TMEM98 ([Fig 4A and 4B](#pone.0227435.g004){ref-type="fig"} and [S7A--S7C Fig](#pone.0227435.s007){ref-type="supplementary-material"}).

![TMEM98 negatively regulates FRAT protein levels.\
(A) Quantification of myc-FRAT2 protein levels upon co-transfecting increasing concentrations of TMEM98-sGFP2 or TMEM98-mTq2 fusion constructs, confirming that increasing concentrations of TMEM98 result in a reduction in myc-FRAT2 protein levels. Graph depicts data from n = 9 independent experiments. Boxes depict the spread of the data. Horizontal bars depict the median value. For each experiment, myc-FRAT2 protein levels in the absence of TMEM98 were set to 1. (B) Representative example of a Western blot from the experiments quantified in (A). HSP90 serves as a loading control. (C-D) Western blot of lysates from transiently transfected HEK293T cells, showing that knocking down either endogenous (first three lanes) or transiently transfected TMEM98-FLAG (next three lanes) and TMEM98ΔN-FLAG (last three lanes) results in an increase in both myc-FRAT1 (C) and myc-FRAT2 (D) protein levels. pRS = pRetrosuper, the empty vector control for RNAi constructs \#2 and \#3. Endogenous GSK3ß serves as a loading control. (E) Dual luciferase reporter assay in transiently transfected HEK293T cells, quantifying the effects of knocking down endogenous Tmem98 using the most efficient RNAi (\#3) on FRAT induced TOPFLASH reporter activity. Graph depicts data from n = 4 (FRAT1) or n = 5 (FRAT2) independent experiments, with each data point representing the average of three technical replicates. Boxes depict the spread of the data. Horizontal bars depict the median value. TOPFLASH luciferase values are normalized to CMV-Renilla, which was included as a transfection control. For each individual experiment the baseline TOPFLASH luciferase reporter activity in HEK293T cells transfected with empty vector (instead of myc-Frat1 or myc-Frat2) was set to 1. (F) Same as in (E), but this time the TOPFLASH luciferase reporter activation in the absence of a Tmem98 knockdown was set to 100%. Only statistically significant differences (one-way ANOVA, Tukey's multiple comparisons test) are indicated with asterisks: \*\*\*\*: P ≤ 0.0001, \*\*\*: P ≤ 0.001, \*\*: P ≤ 0.01.](pone.0227435.g004){#pone.0227435.g004}

To further substantiate that TMEM98 controls FRAT protein levels, we knocked down *Tmem98* expression, reasoning that this should at least partially restore FRAT protein levels. Of the three RNAi constructs designed, two efficiently reduced both TMEM98 and TMEM98ΔN protein levels ([S6 Fig](#pone.0227435.s006){ref-type="supplementary-material"}). Western blot analysis showed that both FRAT1 and FRAT2 protein levels indeed increased when either *Tmem98-FLAG* or *Tmem98ΔN-FLAG* expression was knocked down ([Fig 4C and 4D](#pone.0227435.g004){ref-type="fig"}). The RNAi constructs were designed to also recognize endogenous *TMEM98* in HEK293T cells. Importantly, knocking down endogenous TMEM98 expression also resulted in an increase in FRAT1 and FRAT2 protein levels ([Fig 4C and 4D](#pone.0227435.g004){ref-type="fig"}). This translated to an increase in TOPFLASH reporter activity ([Fig 4E and 4F](#pone.0227435.g004){ref-type="fig"}), with our most efficient knockdown construct (*TMEM98 RNAi \#3*) causing an average 1.7-fold and 1.6-fold increase in TOPFLASH induction by myc-FRAT1 (from 15.3 ± 8.1 to 26.7 ± 6.0) and myc-FRAT2 (from 5.4 ± 3.3 to 8.5 ± 3.1), respectively. Together, these results confirm that TMEM98 inhibits FRAT function by reducing FRAT protein levels.

TMEM98 undergoes retrograde trafficking {#sec007}
---------------------------------------

A previous study showed TMEM98 to be secreted in its full-length form, presumably via exosomes \[[@pone.0227435.ref030]\]. Whereas exosomes originate from multivesicular bodies (MVBs), our results suggest that TMEM98 reaches the plasma membrane via the classical secretory pathway (i.e. via the ER/Golgi, [Fig 2](#pone.0227435.g002){ref-type="fig"}).

However, when we analysed publicly available protein-protein interaction data using the BioGRID tool \[[@pone.0227435.ref031],[@pone.0227435.ref032]\], we noticed an interaction between TMEM98 and multiple proteins that are associated with late (STX7, STX8, VT1B, VAMP8) and/or recycling endosomes (STX6, STX12, VAMP3). In addition, TMEM98 was also picked up in a yeast-two-hybrid screen as a binding partner of RABEPK, a Rab9 effector that is required for transport from endosomes to the trans-Golgi network \[[@pone.0227435.ref033],[@pone.0227435.ref034]\]. Although none of these interactions have been verified in living cells thus far, these findings suggest that TMEM98 may undergo retrograde trafficking ([S8 Fig](#pone.0227435.s008){ref-type="supplementary-material"}). Using confocal microscopy, we found that the TMEM98-GFP signal partially overlapped with that of the early endosome marker EEA1 ([Fig 5A](#pone.0227435.g005){ref-type="fig"}), a RAB5 effector and binding partner of STX6 \[[@pone.0227435.ref035],[@pone.0227435.ref036]\]. From this, we conclude that TMEM98 indeed enters the endocytic pathway.

![TMEM98 is recycled between the Golgi and the plasma membrane.\
(A) Confocal microscopy images of fixed 293A cells, showing co-localization of TMEM98 and early endosomes. Green: Transiently transfected TMEM98-AcGFP (direct detection of GFP signal). Magenta: Immunofluorescent staining of endogenous EEA1. Scale bar is 10 μm. (B) Confocal microscopy images of live HeLa cells, showing partial overlap of TMEM98 and lysosomes. Green: Transiently transfected TMEM98-mTq2 (direct detection of mTq2 signal). Magenta: Lysotracker red dye (direct fluorescent detection). Scale bar is 10 μm. (C) Confocal microscopy images of live HeLa cells, showing close proximity but incomplete overlap of TMEM98 and lysosomes. Green: Transiently transfected TMEM98-mTq2 (direct detection of mTq2 signal). Magenta: Transiently transfected LAMP1-mCherry (direct detection of mCherry signal). Scale bar is 2 μm. (D) Confocal microscopy image of fixed HeLa cells, transiently transfected with TMEM98-mTq2 and highlighting the tubular appearance of TMEM98-positive vesicular structures (direct detection of mTq2 signal). Scale bar is 1 μm. (E) Confocal microscopy images of live HeLa cells, showing co-localization of TMEM98 and recycling endosomes. Green: Transiently transfected TMEM98-mTq2 (direct detection of mTq2 signal). Magenta: Transiently transfected Rab9a-mCherry (direct detection of mCherry signal). Scale bar is 10 μm. (F) Confocal microscopy images of live HeLa cells, showing co-localization of TMEM98 and late endosomes. Green: Transiently transfected TMEM98-mTq2 (direct detection of mTq2 signal). Magenta: Transiently transfected Rab7-mCherry (direct detection of mCherry signal). Scale bar is 10 μm. (G) Confocal microscopy images of fixed 293A cells, showing co-localization of TMEM98 and late endosomes. Green: Transiently transfected TMEM98-AcGFP (direct detection of GFP signal). Magenta: Immunofluorescent staining of endogenous MPR. Scale bar is 10 μm. (A-G) Yellow arrowheads indicate co-localization, blue arrowheads indicate no co-localization.](pone.0227435.g005){#pone.0227435.g005}

To further follow its intracellular trafficking, we first tested whether TMEM98 reaches the lysosomal compartment. The signal of TMEM98-mTq2, which is still fluorescent at low intracellular pH \[[@pone.0227435.ref037]\] only occasionally overlapped with that of a lysosomal dye ([Fig 5B](#pone.0227435.g005){ref-type="fig"}). In addition, although TMEM98-positive vesicles were frequently found in close proximity to LAMP1-positive lysosomes, we were ultimately unable to confidently determine that the two indeed co-localized ([Fig 5C](#pone.0227435.g005){ref-type="fig"}). TMEM98-FLAG protein turnover was unchanged by the lysosomal inhibitor bafilomycin ([S9 Fig](#pone.0227435.s009){ref-type="supplementary-material"}). Thus, we were unable to find conclusive evidence for either lysosomal targeting or degradation of TMEM98.

While performing these experiments, we noticed that many of the intracellular TMEM98-positive structures had a more tubular appearance ([Fig 5D](#pone.0227435.g005){ref-type="fig"} and other examples), which is in agreement with that of endosomal recycling domains \[[@pone.0227435.ref038]--[@pone.0227435.ref040]\]. Indeed, we detected TMEM98-mTq2 in multiple endosomal compartments, as evidenced by its co-localization with RAB9A (involved in retrograde transport to the trans-Golgi network, [Fig 5E](#pone.0227435.g005){ref-type="fig"}) and RAB7 (present on maturing and late endosomes, [Fig 5F](#pone.0227435.g005){ref-type="fig"}). In addition, we found the TMEM98-GFP signal to also show partial overlap with that of the mannose-6-phosphate receptor (MPR), which is recycled to the trans-Golgi network from late endosomes in a RAB9-dependent manner ([Fig 5G](#pone.0227435.g005){ref-type="fig"}) \[[@pone.0227435.ref041]\]. Together, our data suggest that TMEM98 traffics between multiple endosomal compartments, is recycled between the Golgi and the plasma membrane, but largely escapes lysosomal degradation.

Discussion {#sec008}
==========

Wnt signal transduction is tightly controlled. Multiple agonists and antagonists modify activity of the Wnt/ß-catenin pathway at the ligand and receptor level, with DKK and RSPO serving as prominent examples \[[@pone.0227435.ref042]--[@pone.0227435.ref048]\]. Wnt-signalling strength can also be modulated intracellularly. For instance, expression of the negative feedback regulator *Axin2* is induced in virtually all cells with active Wnt/ß-catenin signalling \[[@pone.0227435.ref049],[@pone.0227435.ref050]\]. This ensures re-association of the destruction complex and dampening of the CTNNB1/TCF signalling response. In contrast, FRAT proteins are positive regulators of the Wnt/ß-catenin pathway. Their GSK3-binding activity allows initiation or amplification of the CTNNB1/TCF response even in the absence of a WNT stimulus. However, little remains known about their physiological function or their precise regulation at the molecular level.

Here we characterize TMEM98 as a novel negative regulator of FRAT and an inhibitor of FRAT-induced CTNNB1/TCF signalling. TMEM98 binds FRAT2, resulting in a reduction in FRAT2 protein levels and a concomitant decrease in FRAT2 signalling activity (Figs [1](#pone.0227435.g001){ref-type="fig"}, [3](#pone.0227435.g003){ref-type="fig"} and [4](#pone.0227435.g004){ref-type="fig"}). Because TMEM98 protein levels did not increase linearly in the presence of FRAT2, as opposed to when TMEM98 was transfected alone ([Fig 4B](#pone.0227435.g004){ref-type="fig"} and [S7A--S7D Fig](#pone.0227435.s007){ref-type="supplementary-material"}), our findings are consistent with a model in which TMEM98 and FRAT2 form a negative feedback loop ([S7E Fig](#pone.0227435.s007){ref-type="supplementary-material"}). As such, TMEM98 and FRAT2 may constitute a dynamic regulatory switch with the capacity to fine-tune CTNNB1/TCF signalling activity. TMEM98 also binds and inhibits FRAT1, but whether TMEM98 affects the biological activity of both homologues to the same extent remains to be determined.

Our experiments largely agree with topology predictions and previous findings by confirming that TMEM98 localizes to the plasma membrane via an N-terminal membrane anchor ([Fig 2](#pone.0227435.g002){ref-type="fig"}). However, where most algorithms predict TMEM98 to be a single-pass type I transmembrane protein with an intracellular C-terminus, our results confirm that TMEM98 has an extracellular C-terminus, as proposed previously \[[@pone.0227435.ref051]\]. From our yeast-two-hybrid screen we can conclude that amino acids 109--217 of TMEM98 interact with FRAT2 ([S2 Fig](#pone.0227435.s002){ref-type="supplementary-material"}). Given that FRAT2, as far as we know, is a soluble cytoplasmic protein, these findings raise an interesting conundrum: if TMEM98 indeed has an extracellular C-terminus, then where does it encounter and interact with FRAT? We present two possible scenarios ([Fig 6](#pone.0227435.g006){ref-type="fig"}).

![Model for FRAT and TMEM98 interaction.\
Schematic representation of possible TMEM98 topologies and trafficking activities based on in silico prediction algorithms and our experimental data. Given that most algorithms predict TMEM98 to be a single-pass transmembrane protein and our data confirm that the C-terminus of the protein is located on the extracellular surface, model A (left) is the most likely scenario. However, it would require TMEM98 and FRAT to interact in the endosomal compartment, for which no evidence is available to date. The alternative model B (right) assumes the presence of a second transmembrane domain, to allow exposure of a cytosolic FRAT-binding domain. Depiction of the endosomal trafficking and sorting compartments is based on the previously reported association of different Rab proteins with specific endosomal domains \[[@pone.0227435.ref040],[@pone.0227435.ref052]--[@pone.0227435.ref055]\].](pone.0227435.g006){#pone.0227435.g006}

If TMEM98 is a single-pass type II protein with its entire C-terminus located extracellularly, logic dictates that the only intracellular location where interaction between TMEM98 and FRAT could take place would be inside early or late endosomes ([Fig 6](#pone.0227435.g006){ref-type="fig"}, Model A), the contents of which are either recycled, targeted for lysosomal degradation or secreted in exosomes. Although neither FRAT1 nor FRAT2 have yet been shown to localize to the endosomal compartment, other WNT/ß-catenin signalling components, including GSK3, have \[[@pone.0227435.ref056]--[@pone.0227435.ref058]\]. Obviously, targeting of FRAT to either lysosomes or exosomes would result in a reduction of FRAT protein levels. Although we have so far not been able to find experimental support for either of these scenarios, our immunoprecipitation experiments support the fact that only a small proportion of the total FRAT2 protein pool interacts with TMEM98 ([Fig 1](#pone.0227435.g001){ref-type="fig"}). Alternatively, the presence of a second transmembrane domain in TMEM98 would create and intracellular loop and potential binding site that would be capable of interacting with the cytoplasmic pool of FRAT ([Fig 6](#pone.0227435.g006){ref-type="fig"}, Model B). Of note, the DAS-TMfilter algorithm indicates the presence of a second, more C-terminal, transmembrane domain (TM2, [Fig 1A](#pone.0227435.g001){ref-type="fig"}, [S1C Fig](#pone.0227435.s001){ref-type="supplementary-material"} and [Table 3](#pone.0227435.t003){ref-type="table"}) and, accordingly, predicts TMEM98 to be a dual pass transmembrane protein. Other algorithms (Phobius & TMpred) also detect this domain, but indicate it as non-significant. However, it should be noted that a previous study detected TMEM98 on the extracellular cell surface using an antibody with an epitope immediately downstream of the N-terminal transmembrane helix \[[@pone.0227435.ref030]\]. This makes the existence of such an intracellular, cytoplasmic loop less likely.

Interestingly, the *Xenopus* FRAT homologue, GBP, has previously been found to bind to Kinesin light chain (KLC) and, as such, to be transported along microtubules during the process of cortical rotation in early frog embryogenesis \[[@pone.0227435.ref059]\]. It is tempting to speculate that FRAT and TMEM98 could be similarly transported. Perhaps they are more broadly involved in endocytic trafficking in mammalian cells, which is also known to occur along microtubules in a kinesin-dependent manner \[[@pone.0227435.ref060]\]. Of course, we cannot exclude other possibilities. Theoretically, TMEM98 can also exist in two different confirmations: a single pass type I and type II protein that could flip its orientation at the plasma membrane, as has been shown to occur upon changes in lipid composition \[[@pone.0227435.ref061]\]. Which, if any, of these models is correct and how this would ultimately result in a reduction in FRAT protein levels, remains to be tested.

Both FRAT and TMEM98 have been shown to have oncogenic activity \[[@pone.0227435.ref016],[@pone.0227435.ref023],[@pone.0227435.ref024],[@pone.0227435.ref062],[@pone.0227435.ref063]\]. While the physiological role of FRAT proteins is still elusive \[[@pone.0227435.ref022]\], TMEM98 has been genetically linked to autosomal dominant nanophthalmos \[[@pone.0227435.ref025],[@pone.0227435.ref026]\], a developmental disorder resulting in small eyes, hyperopia and an increased risk of angle closure glaucoma. A molecular and cellular explanation for the involvement of TMEM98 in eye development and the onset of nanophthalmos is still missing. Of note, TMEM98 was recently reported to bind and prevent the self-cleavage of MYRF, an ER associated membrane-bound transcription factor \[[@pone.0227435.ref064]\]. MYRF itself has since been linked to nanophthalmos in humans and retinal degeneration in mice \[[@pone.0227435.ref065]\], similar to TMEM98 \[[@pone.0227435.ref066]\]. It will be interesting to determine if and how the FRAT-binding and vesicular trafficking activities of TMEM98 contribute to its biological function in this setting.

Materials and methods {#sec009}
=====================

Yeast two-hybrid screening {#sec010}
--------------------------

Full-length murine *Frat2* (encoding amino acids 1--232) or a deletion mutant starting at an internal SmaI site (*Frat2ΔN*, encoding amino acids 139--232) were cloned in a *LexA* C-terminal fusion vector provided by Hybrigenics. Constructs were confirmed to be in frame by Sanger sequencing.

Yeast two-hybrid (Y2H) screening was performed by Hybrigenics, S.A., Paris, France ([http://www.hybrigenics.com](http://www.hybrigenics.com/)). Shortly, the bait construct was transformed in the L40ΔGAL4 yeast strain \[[@pone.0227435.ref067]\]. A Human fetal brain random-primed cDNA library, transformed into the Y187 yeast strain and containing ten million independent fragments, was used for mating. The screen was first performed on a small scale to adapt the selective pressure to the intrinsic property of the bait. For full-length *Frat2*, no auto-activation of the bait was observed. The *Frat2ΔN* bait was found to auto-activate the Y2H system, and 50mM 3-aminotriazole was found to be the optimal concentration to reduce background colonies. Next, the full-scale screen was performed in conditions ensuring a minimum of 50 million interactions tested, in order to cover five times the primary complexity of the yeast-transformed cDNA library \[[@pone.0227435.ref068]\]. A total of 95 million (*Frat2* screen) and 87 million (*Frat2ΔN* screen) interactions were actually tested. After selection on medium lacking leucine, tryptophane, and histidine, 8 and 141 positive clones were picked for *Frat2* and *Frat2ΔN*, respectively, and the corresponding prey fragments were amplified by PCR and sequenced at their 5\' and 3\' junctions.

Sequences were then filtered as described previously \[[@pone.0227435.ref069]\] and compared to the latest release of the GenBank database using BLASTN \[[@pone.0227435.ref070]\]. A Predicted Biological Score (PBS) was assigned to assess the reliability of each interaction \[[@pone.0227435.ref067],[@pone.0227435.ref068]\]. First, a local score takes into account the redundancy and independency of prey fragments, as well as the distributions of reading frames and stop codons in overlapping fragments. Second, a global score takes into account the interactions found in all the screens performed at Hybrigenics using the same library. In addition, potential false-positives are flagged by a specific "E" PBS score. This is done by discriminating prey proteins containing "highly connected" domains, previously found several times in screens performed on libraries derived from the same organism. Raw data of the yeast-two-hybrid screen are available via the Open Science Framework at <http://dx.doi.org/10.17605/OSF.IO/EF74W>.

DNA constructs {#sec011}
--------------

The *pGlomyc-Frat1* and *pGlomyc-Frat2* plasmids were described previously \[[@pone.0227435.ref011],[@pone.0227435.ref012]\]. The full-length coding sequence of murine *Tmem98* was amplified from a mix of murine embryonic and murine keratinocyte cDNA using forward `5’-AAAAAGCTTGCCATGGAGACTGTGGTGATCGTC-3’` and reverse `5’-TTTTGAATTCTTAAATGGCCGACTGTTCCTGCAGGAAGC-3’` primers and cloned into pSP72 (Promega) as a HindIII/EcoRI fragment. A *FLAG* tag was inserted at the C-terminus via a PstI/EcoRI restriction digest. The *Tmem98-FLAG* cassette was cloned into pCDNA3.1 as a HindIII/HindIII fragment. The deletion mutant *Tmem98ΔN-FLAG* was generated by deleting the first 34 amino acids using an internal XhoI site. A slightly modified construct, in which a stretch of superfluous amino acids was removed by insertion of a HindIII/EcoRI oligomer behind the C-terminus of Tmem98, was used for most of the experiments.

A Tmem98-AcGFP fusion construct was generated by cloning the Tmem98 coding sequence into the SmaI cut pAc-GFP-N2 vector (Clontech). TMEM98-AcGFP did not inhibit FRAT2 activity to a similar extent as TMEM98-FLAG (data not shown). Because AcGFP has the tendency to dimerize \[[@pone.0227435.ref071]\], we later replaced this construct with *Tmem98-SGFP2*. Because GFP is not fluorescent at lower pH, we also generated *Tmem98*-*mTurquoise2* and *Tmem98-mCherry* fusions. This was achieved by exchanging *AcGFP1* with either *sGFP2*, *mTurquoise2 (mTq2)* or *mCherry* fragments using a BamHI/BsrGI digest.

*Tmem98* knockdown constructs were generated by annealing sense and antisense oligo's and cloning the annealed products into pRetrosuper (a gift from Dr. Thijn Brummelkamp, Netherlands Cancer Institute). Knockdown constructs recognize both mouse *Tmem98* and human *TMEM98* based on sequence homology. Sense oligo sequences: `5’-GATCCCCCTGGAAGCATGGAGACTGTTTCAAGAGAACAGTCTCCATGCTTCCAGTTTTTGGAAA-3’` (RNAi1), `5’-GATCCCCCCATCTTGAAGATTTGTCATTCAAGAGATGACAAATCTTCAAGATGGTTTTTGGAAA-3’` (RNAi2) and `5’-GATCCCCACATCATTGTGGTGGCCAATTCAAGAGATTGGCCACCACAATGATGTTTTTTGGAAA-3’` (RNAi3).

Additional constructs used were Lck-mCherry, Rab7-mCherry and Lamp1-mCherry (a gift from Dr. Joachim Goedhart, University of Amsterdam); Rab9a-mCherry (Addgene plasmid \#78592, donating investigator Yihong Ye \[[@pone.0227435.ref072]\]), pLenti-CMV-rtTA3 Hygro (Addgene plasmid \#26730, donating investigator Eric Campeau), pTREtight2 (Addgene plasmid \#19407, donating investigator Markus Ralser), CMV-Renilla (Promega) and MegaTOPFLASH (a gift from Dr. Christophe Fuerer and Dr. Roel Nusse, Stanford University).

To create a stable doxycycline-inducible TMEM98-FLAG cell line, *Tmem98-FLAG* was amplified by PCR from *pCDNA3*.*1-Tmem98-FLAG* and inserted into pTREtight2 as an EcoRI/EcoRI fragment. All constructs were verified by restriction enzyme digestion analysis and Sanger sequencing prior to use.

The following constructs will be made available via Addgene: *pGlomyc-Frat1* (plasmid \#124499), *pGlomyc-Frat2* (\#124500), *pCDNA3*.*1-Tmem98-FLAG* (\#124501), *pCDNA3*.*1*-*Tmem98ΔN-FLAG* (\#124502), *Tmem98-sGFP2* (\#124503), *Tmem98-mTq2* (\#124504), *Tmem98-mCherry* (\#124505) and *pTRE-tight2-Tmem98-FLAG* (\#124504).

Cell culture and transfection {#sec012}
-----------------------------

HEK293TN (a gift from Dr. Anton Berns), HEK293A (a gift from Dr. Anton Berns) and HeLa cells (a gift from Dr. Joachim Goedhart) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Gibco) under 5% CO2 at 37°C in humidifying conditions. On the day prior to transfection, cells were plated in 6-well tissue culture plates, 12-well tissue culture plates, or 8-well chamber slides. Cells were transfected with a total amount of 200 ng DNA (per 8-chamber slide), 500 ng DNA (per well of a 12-well plate) or 1500 ng DNA (per well of a 6-well plate) using polyethylenimine (PEI, Polysciences Inc., dissolved at 1 mg/ml in ethanol). Transfection mixtures were made in Optimem using a 1:3 ratio (μg:μl) of DNA and PEI. In all cases, empty pGlomyc vector was added to control for the total amount of DNA transfected. Master mixes were made where possible to reduce variation.

To generate a stable doxycycline inducible TMEM98-FLAG cell line, HEK293TN cells were transfected with the *pTREtight2-Tmem98-FLAG* and *pLenti-CMV-rtTA3-Hygro* constructs. Following hygromycin selection, individual clones were picked and tested for TMEM98 induction by Western blot analysis. FACS analysis revealed that even within a clonal population of cells, not all cells induced TMEM98-FLAG expression. Subcloning did not solve this problem, suggesting that some cells had either lost or randomly silenced the construct.

Where indicated, cells were treated with MG132 (Sigma-Aldrich), bafilomcycin (Sigma-Aldrich) or Brefeldin A (Sigma Aldrich) for the times mentioned.

Protein gels and Western blot analysis {#sec013}
--------------------------------------

HEK293TN cells transfected as described above with the indicated constructs were harvested 48 hours post-transfection by lysis in RIPA buffer supplemented with protease inhibitors (Roche) or in passive lysis buffer (Promega). Protein concentration was determined using a colorimetric assay (BioRad) or Pierce BCA protein assay (Thermo Scientific).

For immunoprecipitation, HEK293TN cells were transfected in a 6-well plate. Protein lysates were incubated at 4°C with a mouse monoclonal antibody directed against the FLAG-tag (M2, Stratagene). Immunocomplexes were pulled down by incubation with protein G sepharose, after which samples were washed in RIPA buffer to remove unbound protein, resuspended in RIPA buffer, run on precast protein gels (either 10% or 4%-12%, Nupage) and analyzed on Western blot. Equal amounts of protein were prepared in passive lysis buffer with protein loading buffer (125 mM Tris-HCl (pH 6.8), 50% glycerol, 4% SDS, 0.2% Orange-G, 10% betamercaptoethanol) and samples were boiled at 95˙C prior to loading.

For the Western blots that gave rise to [Fig 2G](#pone.0227435.g002){ref-type="fig"}, [Fig 4B](#pone.0227435.g004){ref-type="fig"} and [S7A--S7C Fig](#pone.0227435.s007){ref-type="supplementary-material"} and [S9 Fig](#pone.0227435.s009){ref-type="supplementary-material"}, samples were run on 12% SDS-PAGE gel in electrophoresis buffer (25 mM Tris base, 192 mM Glycine, 0.1% SDS) at 80-120V and transferred to 0.2 μm nitrocellulose membrane (Biorad) overnight at 30V. Membranes were blocked in 1:1 TBS:Odyssey Blocking buffer (LI-COR) and incubated overnight at 4˙C with primary antibodies (rabbit anti-TMEM98, Proteintech, 1:1000; rabbit anti-FLAG polyclonal, Sigma, 1:2000; mouse anti-FLAG monoclonal M2, Stratagene 1:2000, mouse anti-myc monoclonal 9E10, Invitrogen, 1:5000; mouse anti-myc monoclonal 9B11, Cell Signaling Technologies, 1:1000; mouse anti-tubulin, Sigma-Aldrich, 1:1000; mouse anti-Hsp90a/b, mouse, Santa-Cruz, 1:1000, mouse anti-GSK3ß, BD Transduction labs, 1:2000) in TBS:Odyssey Blocking buffer supplemented with 0.1% Tween-20. Secondary antibody (anti-mouse 680, LI-COR, 1:20,000; anti-rabbit 800, LI-COR, 1:20,000) incubation was performed in TBS-T for 45 minutes at room temperature. Membranes were stored at 4˙C in TBS and imaged on an Odyssey Fc (LI-COR) for two minutes at 680 nm and 800 nm. These blots were used for quantification. For the Western blots depicted in [Fig 1B and 1C](#pone.0227435.g001){ref-type="fig"}, [Fig 4C and 4D](#pone.0227435.g004){ref-type="fig"}, [S5 Fig](#pone.0227435.s005){ref-type="supplementary-material"} and [S6 Fig](#pone.0227435.s006){ref-type="supplementary-material"}, samples were run on precast protein gels (either 10% or 4%-12%, Nupage) and blots were imaged using ECL detection (Pierce) instead, after labelling with goat-anti-mouse-HRP and goat-anti-rabbit-HRP secondary antibodies. These blots were not used for quantification, since it could not be excluded that some of the signal on the film was oversaturated. Original Western blot files are available via the Open Science Framework at <http://dx.doi.org/10.17605/OSF.IO/EF74W>.

Luciferase assay {#sec014}
----------------

For luciferase assay experiments, triplicate transfections were performed in 12-well plates. For each well, HEK293TN cells were transfected with 500 ng DNA total (usually 100 ng MegaTOPFLASH, 50 ng CMV-Renilla and different amounts (25, 50, 100, 200 ng) of myc-Frat2 and Tmem98 constructs as required, supplemented with empty pGlomyc vector as carrier DNA. Cells were harvested 48 hours post-transfection in passive lysis buffer (Promega) and analysed with by dual luciferase assay in a Lumat LB 9507 Luminometer (Berthold Technologies) or a GloMax navigator (Promega). For each replicate, 10 μl of lysate was transferred to a black 96-well Optiplate using 50 μl of Firefly and 50 μl of Renilla detection reagents (reagents were either from Promega or home-made, according to a protocol shared by Dr. Christophe Fuerer). The ratio of Firefly:Renilla values was used as a measure of TOPFLASH activation. Within each experiment, all data were normalized to empty pGlomyc transfected cells, the Firefly:Renilla ratio of which was set to 1. Experiments were performed at least three times. For Western blot analyses of luciferase assay experiments, the lysates from triplicate wells were pooled after the luciferase assay measurements were performed.

FACS analysis {#sec015}
-------------

A stable, doxycycline-inducible, clonal *tetO-Tmem98/CMV-rtTA3* HEK293TN cell line was treated with doxycycline (1 μg/ml) for 24 hours to induce TMEM98-FLAG expression. Vehicle treated cells were taken along as a negative control. Cells were then washed with PBS, trypsinized, and resuspended in HBSS/5%FBS. A small aliquot was taken as an unfixed, unstained control sample. For extracellular staining, unfixed cells were stained with an anti-FLAG M2 antibody (1:100, Sigma) on ice for 20 minutes, followed by labelling with a secondary antibody Donkey-anti-Mouse Alexa 488 (1:500, Molecular Probes) on ice for 20 minutes. For total intracellular and extracellular staining, cells were dissolved in 100 ul of Fixation/Permeabilization buffer A (BD Biosciences) and incubated at room temperature for 15 minutes. Following a wash with HBSS/5%FBS, cells were incubated with 100 ul Permeabilization buffer B (BD Biosciences) prior to staining with the anti-FLAG and Donkey/Mouse Alexa488 antibodies as described above. Cells were then washed in HBSS/5% FCS, dissolved in 400 ul HBSS/5% FBS and analysed on a BD FACS AriaIII. Note that we cannot exclude that trypsinization may have resulted in partial cleavage of the FLAG-tagged C-terminus of TMEM98, which may have resulted in an underestimation of the signal.

Confocal microscopy {#sec016}
-------------------

For immunofluorescence analysis, cells were plated in 8-well chamber slides and transfected on either the same day or the following day with a total amount of 200 ng (per 8-chamber slide) DNA using PEI. For direct fluorescent detection of fluorescent fusion proteins, cells were seeded onto glass coverslips in a 6 well plate and transfected with a total amount of 500 ng DNA per well.

Cells were imaged at 48 hours after transfection. The experiments depicted in [Fig 2A](#pone.0227435.g002){ref-type="fig"}, [Fig 6B](#pone.0227435.g006){ref-type="fig"} and [Fig 6C](#pone.0227435.g006){ref-type="fig"} were performed on live cells in microscopy medium (20 mM HEPES, pH 7.4; 137 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, 20 mM glucose). Lysotracker red (Invitrogen) was added 5--15 minutes prior to analysis. For all other imaging experiments, cells were fixed in 4% paraformaldehyde or ice-cold methanol. For fluorescent protein detection, cells were washed in PBS and mounted in Mowiol mounting medium. For immunofluorescence staining, cells were permeabilized with 0.2% Triton-X100 or 0.1% Saponin and stained with antibodies directed against the FLAG tag (M2, Sigma, 1:400), Golgin97 (CDF4, Molecular Probes, 1:100), EEA1 (BD Biosciences, 1:100--1:200) and MPR (1:100--1:200). Nuclei were counterstained with TOPRO3 or DAPI. Secondary antibodies were Alexa conjugated Goat-anti-Mouse, Donkey-anti-Mouse or Goat-anti-Rabbit antibodies with Alexa 488, 568 or 633 dyes. Samples were imaged by sequential scanning on a Leica SP2 or SP8, or a Nikon A1 confocal microscope, using 405nm, 457nm, 488nm, 561nm and 633nm lasers and appropriate filter blocks or AOBS settings.

Software, in silico analysis and online repositories {#sec017}
----------------------------------------------------

Image studio Lite (LI-COR) was used for quantitative Western blot analysis. Luciferase experiments were analysed in Excel. Graphs were made in GraphPad Prism and R Studio. Statistical testing was performed in GraphPad Prism. FACS data were analysed with FlowJo software.

Confocal microscopy images were processed in Fiji. Overlays were made using the Image5D plugin, using green and magenta for dual channel overlays. For single channel images, appropriate LUTs were selected for contrast and visualization purposes. Figures were made in Adobe Illustrator.

Online topology prediction algorithms (HMMTOP; Phobius; TMHMM; TMpred; DAS-TMfilter, PrediSi, SignalP 4.1, WOLF PSORT, PredictProtein, SherLoc2, Secretome 2.0) were used to predict the TMEM98 topology (Tables [3](#pone.0227435.t003){ref-type="table"} and [4](#pone.0227435.t004){ref-type="table"}).

Multiple sequence alignments were made at [https://www.ebi.ac.uk](https://www.ebi.ac.uk/) using data extracted from the Ensembl genome database ([https://www.ensembl.org](https://www.ensembl.org/)) as input ([Fig 1](#pone.0227435.g001){ref-type="fig"} and [S1](#pone.0227435.s001){ref-type="supplementary-material"} and [S2](#pone.0227435.s002){ref-type="supplementary-material"} Figs). Version 3.4 of the BioGRID protein-protein interaction database was accessed on 9 June 2018 at [https://thebiogrid.org](https://thebiogrid.org/) ([S8 Fig](#pone.0227435.s008){ref-type="supplementary-material"}). Evolutionary Conserved Regions in human TMEM98 ([Fig 1](#pone.0227435.g001){ref-type="fig"} and [S1 Fig](#pone.0227435.s001){ref-type="supplementary-material"}) were determined using the Aminode Evolutionary Analysis tool available at [http://www.aminode.org](http://www.aminode.org/). \[[@pone.0227435.ref073]\]. The LIFEdb database \[[@pone.0227435.ref027]--[@pone.0227435.ref029]\] was accessed at <https://www.dkfz.de/en/mga/Groups/LIFEdb-Database.html> to find images depicting the subcellular localization of N-terminal and C-terminal TMEM98 fusions ([S3 Fig](#pone.0227435.s003){ref-type="supplementary-material"}).

Supporting information {#sec018}
======================
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Click here for additional data file.

###### TMEM98 clones identified in the yeast two hybrid screen with FRAT2 and FRAT2ΔN.
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###### Improper trafficking of an N-terminal TMEM98 fusion protein.
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###### Interaction between FRAT1, FRAT2 and TMEM98.
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Click here for additional data file.

###### Knock down of TMEM98.

(TIF)
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Click here for additional data file.

###### Non-linear interaction between TMEM98 and FRAT2.
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###### Putative interactors of TMEM98.
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###### TMEM98 is not degraded by the lysosome.

(TIF)

###### 

Click here for additional data file.
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Dear dr. van Amerongen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Both reviewers were enthusiastic about the study but raised significant concerns about the dataset.  Of particular importance are interpretations of the imaging data in Figure 2 and a need for additional statistical analysis, especially Figures 3-5.  Please ensure that you fully address all of the reviewers\' concerns in your revised manuscript.

We would appreciate receiving your revised manuscript by Sep 28 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Koval

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. For reproducibility purposes please modify your methods section to include the source of all cell lines used in this work. If already published, please provide a reference, if obtained commercially or from a colleague, please provide the name of the company/colleague.

3\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

4\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

5\. Thank you for stating the following in the Acknowledgments Section of your manuscript:

This work was funded by a MacGillavry fellowship from the University of Amsterdam (to RvA) and a grant from the Centre of Biomedical Genetics (CBG) to Anton Berns.

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

This work was funded by a MacGillavry fellowship from the University of Amsterdam (to RvA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The FRAT family of proteins have been shown to be activators of Wnt/β-catenin signalling. They act by binding to GSK3 thereby interfering with the assembly of the complex that phosphorylates free CTNNB1 and targets it for degradation. However, FRAT proteins are not required for Wnt signalling in mammals and so they are thought to be modulators. In this paper the authors carry out a yeast 2-hybrid experiment in order to detect proteins that interact with FRAT2 and identify the transmembrane protein TMEM98 as a potential binding partner. They go on to confirm the interaction between the two proteins by co-immunoprecipitation. They then investigate the sub-cellular localisation and topology of TMEM98 and find that it is recycled between the plasma membrane and the Golgi. They also examine the effect of TMEM98 on FRAT activity and protein levels.

Whilst I find the yeast 2-hybrid, interaction data between FRAT2 and TMEM98, the topology data and some of the localisation data to be convincing I do not find some of the other data compelling enough to fully support the conclusions drawn by the authors as outline below.

1\) It does seem strange that GSK3 was not found in the yeast 2-hybrid experiment, this is worthy of discussion.

2\) In Westerns TMEM98-FLAG appears to be a double band (Figs 1, 2 and 4). It appears to be a single band in other Westerns, for example Supplementary Fig 5. Also there are no size markers shown for any of the Westerns. Can the authors comment on this?

3\) In Fig 2A there is clear plasma membrane staining for the tagged TMEM98. Fig 2C shows localisation of TMEM98 to the outer periphery following release from Brefeldin A block. The arrowheads purport to indicate TMEM98 at the periphery 180 minutes after release. I do not find this particularly convincing, it is very hard to see on the printed picture and when enlarged on the screen I can see just a faint blue edge. This is nothing like the pattern of staining seen in Fig 2A. What does an untransfected cell look like? Is there no fluorescent signal?

4\) Fig 2D. For the TMEM98ΔN-AcGFP transfection again all the cells look blue, is this low or no signal?

5\) Fig2E. For the TM1-AcGFP transfection arrowheads are supposed to point to signal at distal protrusions of the ER. Again. very low signal and difficult to see. The authors describe the protein AcGFP as being cytosolic. However the intensity of the heat map suggests to me that the principal place the protein is found is in the nucleus not the cytoplasm.

6\) In the TOPFLASH reporter assays shown in Fig 3 is the effect of TMEM98 on FRAT-induced reporter activity statistically significant? Although we should not be slaves to p values it would be informative to know what they were as there is considerable spread and overlap in the data points. The authors state that TMEM98 reduced the level of CTNNB1/TCF signalling in a dose-dependent manner (Fig 3A) but for the highest amount of TMEM98 the median level of signalling is higher than for all the lower amounts of TMEM98 so this statement is not justified.

7\) The authors conclude that there is a dose-dependent reduction in both FRAT1 and FRAT2 levels caused by increasing amounts of TMEM98 (Fig 4A and Supplementary Fig 5C). By eye it is not convincing to me, the protein levels need to be quantitated to conclude this. The authors do some quantitation shown in Fig 4B and C but the amount of TMEM98-sGFP2 does not look to me as though it increases with increased amount of transfected plasmid. In Fig 4D the level of myc-FRAT1 appears much lower when transfected alone that when it was transfected along with TMEM98-FLAG (compare lanes 1 and 4). Also, there does not appear to be a difference between the signal for FRAT proteins in the presence or absence of full-length TMEM98 in Supplementary Fig 5A. In Supplementary Fig 7A increasing amounts of TMEM98-FLAG are transfected along with a constant amount of myc-FRAT2. However in lane 4 there appears to be less TMEM98-FLAG than in lane 3. In lane 4 the signal for myc-FRAT2 is lower than the adjacent lanes where the amount of TMEM98-FLAG detected is higher. Overall there is a lot of variability among the different experiments. The authors themselves say this on page 7 of the manuscript.

8\) Statistics should be done to test the significance of the TOPFLASH reporter assays shown in Fig 4E and F. There is a great deal of overlap in the pink box (just TMEM98 RNAi) and the blue and green boxes (TMEM98 RNAi along with myc-FRAT1 or myc-FRAT2).

9\) In Supplementary Fig 7B and C the amount of TMEM98-FLAG is kept constant and the amounts of myc-FRAT1 and myc-FRAT2 are increased. The authors conclude that increased myc-FRAT2 increased TMEM98-FLAG levels but to me the signal from lane 1 (TMEM98-FLAG alone) looks extremely similar to the signal in 3 out of 4 of the lanes where increasing amounts of myc-FRAT2 were transfected. It is difficult to reach a convincing conclusion as to the effect of these two proteins on each other's stability.

10\) What do the yellow and blue arrowheads indicate in Fig. 6?

11\) The reference list is duplicated.

Reviewer \#2: In this manuscript, van der Wal described that TMEM98 transmembrane protein interacts with FRAT2 and regulates its activity. The findings are interesting as they reveal a new layer of regulation of Wnt/b-catenin signaling. However, there are several major concerns that need to be addressed prior to publication.

1\. Figure 1：The binding between TMEM98 and FRAT2 appears to be very weak, as judged by the ratio between the FRAT2 band to the background bands which are faint in aFLAG but extremely strong in a-myc staining. This should be explained and discussed.

2\. In consideration of the false positive signal in yeast-two-hybrid assay, the interaction between TMEM98-ΔN and FRAT2 is not shown and should be repeated by co-immunoprecipitation in the presence of the proteasome inhibitor MG132, including Fig S5. It is necessary to show the binding between TMEM98 and FRAT2-ΔN as well.

3\. Figure 2: The data in Fig 2C showed that TMEM98-GFP signals were found to be closely associated with the nucleus in the absence of treatment, suggesting its presence in ER as well. In the presence of Brefeldin A, the signals were restricted to the Golgi, does Brefeldin A disturb the export from distal Golgi compartments to the cell surface (Miller SG, 1992), and does Brefeldin A inhibit protein transport from the Golgi to the ER? If so, these data should suggest that TMEM98 is transported from Golgi to the ER? The extracellular location of TMEM98 C-terminus in Fig 2A was not well verified . Other methods should be performed to substantiate the subcellular localization of TMEM98, such as using the technique defined in (Lorenz H, 2006). And, the TMEM98ΔN-AcGFP was invisible (or the weak signal appeared as blue?) in Fig 2D.

4\. Figure 2H: it is mentioned in methods that cells were treated with trypsin in FACS analysis. However, trypsin will remove the extracellular C-terminus of TMEM98-Flag. Did this affect the results?

5\. Figure 3: since FRAT1 is a more potent activator of CTNNB1/TCF signaling than FRAT2 showed in Fig 3B, is it better to test the inhibition of FRAT1 activities in the presence of TMEM98 in Fig 3A? Meanwhile, the conclusion is not convincing that TMEM98 consistently reduced the level of CTNNB1/TCF signaling in a dose-dependent manner according to Fig 3A (maybe due to the non-linear increase in TMEM98 protein levels). Did the level of phosphorylated β-catenin proteins change when transfected with TMEM98 and FRAT1/2?

6\. As TMEM98-AcGFP protein does not inhibit FRAT2 activity to the same extent as TMEM98-FLAG and TMEM98-mCherry, it may not be suitable for subcellular tracing TMEM98 proteins in Fig 2 and Fig 6.

7\. If the model in Fig 7B is correct, we would expect that the region between two transmembrane domains would interact with FRAT. Is this true?

References:

Lorenz H,Hailey DW and Lippincott-Schwartz J. Fluorescence protease protection of GFP chimeras to reveal protein topology and subcellular localization. Nat Methods, 2006, 3(3): 205-210.

Miller SG,Carnell L and Moore HH. Post-Golgi membrane traffic: brefeldin A inhibits export from distal Golgi compartments to the cell surface but not recycling. 1992, 118(2): 267-283.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to specific editor comments:

As indicated in your decision letter (PONE-D-19-18523), we have paid particular attention to the following:

\- For the presentation and interpretation of the imaging data in Figure 2, we have changed the LUT for some of the figure panels to provide better contrast. We have also modified some of the main text in our manuscript to prevent overinterpretation of our data.

\- For Figures 3-5 we have performed statistical testing as requested. We have also included new Western blots with quantification, since both reviewers commented on the variability of the data.

Please note, that the overall interpretation of our data has not changed. Additional details and background are provided in the attached rebuttal letter.

As for compliance with PLOS ONE journal requirements, we have ensured the following:

1\. All of the files in our resubmission meet PLOS ONE style requirements.

2\. The sources of all cell lines have been indicated in the methods section.

3\. All original uncropped and unadjusted images underlying the blot and gel results have been posted at a public data repository at <https://osf.io/ef74w/> (DOI provided in the methods section).

4\. All instances of data not shown have been removed from the manuscript.

5\. We have removed funding-related text from the Acknowledgements section. The funding statement as originally provided is still correct.

Response to specific reviewer comments (also detailed in the attached rebuttal):

We thank both Reviewer \#1 and Reviewer \#2 for their time and effort. Based on their constructive feedback, we have made the required changes to our manuscript. We are confident that we have addressed all of their concerns and that our manuscript has improved as a result.

Reviewer \#1

The FRAT family of proteins have been shown to be activators of Wnt/β-catenin signalling. They act by binding to GSK3 thereby interfering with the assembly of the complex that phosphorylates free CTNNB1 and targets it for degradation. However, FRAT proteins are not required for Wnt signalling in mammals and so they are thought to be modulators. In this paper the authors carry out a yeast 2-hybrid experiment in order to detect proteins that interact with FRAT2 and identify the transmembrane protein TMEM98 as a potential binding partner. They go on to confirm the interaction between the two proteins by co-immunoprecipitation. They then investigate the sub-cellular localisation and topology of TMEM98 and find that it is recycled between the plasma membrane and the Golgi. They also examine the effect of TMEM98 on FRAT activity and protein levels. Whilst I find the yeast 2-hybrid, interaction data between FRAT2 and TMEM98, the topology data and some of the localisation data to be convincing I do not find some of the other data compelling enough to fully support the conclusions drawn by the authors as outline below.

We thank Reviewer \#1 for their critical reading and evaluation of our manuscript. We are happy that they find the yeast-two-hybrid data, FRAT2 and TMEM98 interaction data, TMEM98 topology data and most of the localization data convincing, since these data are the foundation for the core message of our manuscript. We also appreciate the reviewer's detailed comments and questions regarding some of the other data, and we want to take the opportunity to address all of their points in more detail below.

1\) It does seem strange that GSK3 was not found in the yeast 2-hybrid experiment, this is worthy of discussion.

Like the reviewer, we were initially surprised that we did not pick up GSK3 in our yeast-two-hybrid screen with full-length FRAT2. We reasoned that perhaps the FRAT2 N-terminus was masking the GSK3-interacting domain under the conditions used for the screen. This was one of the main reasons for repeating the yeast-two-hybrid screen with the N-terminal deletion mutant (FRAT2�N). However, as the reviewer rightly notes, we did not identify GSK3 in the FRAT2�N screen either.

The simplest explanation is that for whatever reason the correct GSK3 clone/functional GSK3 fragment was not present in the yeast-two-hybrid cDNA library used for our Y2H screens. Another reason could be that the interaction between FRAT2 and GSK3 is relatively weak and/or transient. We don't have any actual data to support either one of these scenarios. However, the reviewer might be interested to know, that the lab of Dr. Anton Berns (where this work was initiated) also never picked up GSK3 in any of the FRAT1 yeast-two-hybrid screens that were performed in the mid 1990s (this work remains unpublished).

Since we do not have a clear explanation as to why GSK3 did not show up as an interactor in our yeast-two-hybrid screen (as noted in our revised manuscript on page 5, lines 91-92), we chose not to spend too much space in the manuscript speculating about the potential reasons.

2\) In Westerns TMEM98-FLAG appears to be a double band (Figs 1, 2 and 4). It appears to be a single band in other Westerns, for example Supplementary Fig 5. Also there are no size markers shown for any of the Westerns. Can the authors comment on this?

We apologize for the absence of the protein size markers. This was an omission on our part, which has now been corrected in the revised version of the manuscript. In addition, all of the original, uncropped blots have now also been made available via <https://osf.io/ef74w/> (as per PLOS ONE guidelines).

As for why TMEM98-FLAG appears as a double band on some of our blots but not on others: We hypothesize that the two bands represent different post-translationally modified species of TMEM98, but we have not investigated this further as this was beyond the scope of the current study.

We suspect that the double bands are not visible on all of our blots because not all experiments were performed under the exact same conditions. For instance, some Western blots contain protein lysates made with RIPA lysis buffer that were run on a 4-12% NuPage pre-cast gel, whereas others depict protein lysates made with Promega's passive lysis buffer (e.g. when these samples were also used for luciferase assays) that were run on home-made 12% SDS-page gels. These differences are detailed in the materials and methods section (revised manuscript, pages 29-30).

3\) In Fig 2A there is clear plasma membrane staining for the tagged TMEM98. Fig 2C shows localisation of TMEM98 to the outer periphery following release from Brefeldin A block. The arrowheads purport to indicate TMEM98 at the periphery 180 minutes after release. I do not find this particularly convincing, it is very hard to see on the printed picture and when enlarged on the screen I can see just a faint blue edge. This is nothing like the pattern of staining seen in Fig 2A. What does an untransfected cell look like? Is there no fluorescent signal?

We agree with the reviewer that plasma membrane staining is more clear in some experiments than in others. We can offer multiple explanations for this: First, the experiments were performed in different cell lines (e.g. HeLa versus HEK293A) and with different fixations (e.g. live-cell imaging of unfixed cells, versus 4% PFA or methanol fixation). We observed the clearest plasma membrane staining in living, unfixed HeLa cells (hence the example in Figure 2A). Second, the most prominent plasma membrane signal is not always detected in the same plane (or Z-position) as the ER or the Golgi signal (see Figure 2B as an example, where the focus is on the Golgi rather than the plasma membrane; indicated in the Figure legend (revised manuscript, page 10, lines 183-188). Third, the reviewer is correct in noting that the plasma membrane signal is relatively faint compared to other subcellular structures (including the Golgi), particularly in fixed cells (e.g. Figure 2C). In these images, we set our PMT/gain so as not to oversaturate the most intense signal (Golgi/ER), causing the plasma membrane signal to be relatively low.

In our revised manuscript, we have changed the LUT for Figures 2C-E to improve the contrast/visualization. We think that as a result, the plasma membrane signal (indicated by arrowheads) is now better visible and we hope the reviewer agrees.

4\) Fig 2D. For the TMEM98ΔN-AcGFP transfection again all the cells look blue, is this low or no signal?

A similar point was raised by Reviewer \#2. We include the image below for the reviewers, which also contains the negative control sample for the experiment depicted in Figure 2D. In the image below, we have enhanced the contrast and brightness such that the untransfected control cells (3rd panel) are just barely visible. Thus, the signal for TMEM98�N (2nd panel, as depicted in Figure 2D) is indeed low signal.

When the contrast and brightness of the TMEM98�N transfected cells are adjusted further (4th panel, 'boosted'), the untransfected cells in the well also become visible. In our revision, we have indicated the position of some of these cells with an asterisk in Figure 2D (see also figure legend, revised manuscript, page 10 lines 195-200). In addition, we have changed the LUT for Figures 2C-E for better contrast/visualization. Thus, we hope that the reviewer agrees that the cells transfected with TMEM98�N are indeed expressing low levels of the deletion mutant, which is in agreement with our Western blots result presented in Figure 1.

5\) Fig2E. For the TM1-AcGFP transfection arrowheads are supposed to point to signal at distal protrusions of the ER. Again. very low signal and difficult to see.

Again, we agree with the reviewer that the signal is subtle. In our revised manuscript, we have changed the LUT for Figures 2C-E to improve the contrast/visualization. Because we do not want to over interpret our data, we have removed the specific statement that signal reflects distal protrusions of the ER from the legend of Figure 2 (revised manuscript, pages 10-11, lines 200-203). We have also removed the arrowheads from panel 2E accordingly.

The authors describe the protein AcGFP as being cytosolic. However the intensity of the heat map suggests to me that the principal place the protein is found is in the nucleus not the cytoplasm.

We agree with the reviewer that in the image depicted, the signal is more intense in the nucleus. We have reworded the figure legend to reflect that AcGFP (when not fused to TMEM98) is a free floating fluorescent protein (revised manuscript, page 11, lines 203-205).

We want to point out that it is not uncommon for free floating fluorescent proteins to be distributed across the nucleus and the cytoplasm as a result of diffusion (possible due to their small size). This may well result in the signal appearing to be more intense in the nucleus than in the cytoplasm. For a reference, see Seibel et al. 2007 (<https://www.ncbi.nlm.nih.gov/pubmed/17586454>).

6\) In the TOPFLASH reporter assays shown in Fig 3 is the effect of TMEM98 on FRAT-induced reporter activity statistically significant? Although we should not be slaves to p values it would be informative to know what they were as there is considerable spread and overlap in the data points.

We have performed statistical testing for Figures 3-5 as requested and have updated the figures, figure legends and materials and methods sections accordingly. As can be seen in Figure 3, the inhibitory effect of TMEM98 on FRAT induced reporter activity is statistically significant.

The authors state that TMEM98 reduced the level of CTNNB1/TCF signalling in a dose-dependent manner (Fig 3A) but for the highest amount of TMEM98 the median level of signalling is higher than for all the lower amounts of TMEM98 so this statement is not justified.

We thank the reviewer for pointing this out. A similar point was raised by Reviewer \#2. Given that we only had two data points for this particular condition (i.e. the highest amount of Tmem98), this precludes meaningful statistical testing. Therefore, we have removed this condition from Figure 3A. We have modified the text so as not to overinterpret our data and have removed all instances of "dose-dependent" inhibition. Page 13, lines 263-264 now reads: "Co-transfection experiments showed that TMEM98 reduced the level of CTNNB1/TCF signalling induced by FRAT2 (Fig 3A)." See also point 7 below.

7\) The authors conclude that there is a dose-dependent reduction in both FRAT1 and FRAT2 levels caused by increasing amounts of TMEM98 (Fig 4A and Supplementary Fig 5C). By eye it is not convincing to me, the protein levels need to be quantitated to conclude this. The authors do some quantitation shown in Fig 4B and C but the amount of TMEM98-sGFP2 does not look to me as though it increases with increased amount of transfected plasmid. In Fig 4D the level of myc-FRAT1 appears much lower when transfected alone that when it was transfected along with TMEM98-FLAG (compare lanes 1 and 4). Also, there does not appear to be a difference between the signal for FRAT proteins in the presence or absence of full-length TMEM98 in Supplementary Fig 5A. In Supplementary Fig 7A increasing amounts of TMEM98-FLAG are transfected along with a constant amount of myc-FRAT2. However in lane 4 there appears to be less TMEM98-FLAG than in lane 3. In lane 4 the signal for myc-FRAT2 is lower than the adjacent lanes where the amount of TMEM98-FLAG detected is higher. Overall there is a lot of variability among the different experiments. The authors themselves say this on page 7 of the manuscript.

We appreciate the critical eye of this reviewer.

First, the reviewer is correct in noting that "the amount of TMEM98-sGFP2 does not look to me as though it increases with increased amount of transfected plasmid". This is indeed the case when TMEM98 is co-transfected with FRAT2 (see new Figure 4B and new Supplementary Figure 7 for additional examples). This observation is the reason for proposing the model in new Supplementary Figure 7E (formerly Figure 5B). Given that we don't have definitive proof for this model, we have moved the model from the main figures to the supplementary figures. Accordingly, we moved this section from the results to the discussion, which now reads (revised manuscript, page 21, lines 439-444):

"Because TMEM98 protein levels did not increase linearly in the presence of FRAT2, as opposed to when TMEM98 was transfected alone (Fig 4B and S7A-D Fig), our findings are consistent with a model in which TMEM98 and FRAT2 form a negative feedback loop (S7E Fig). As such, TMEM98 and FRAT2 may constitute a dynamic regulatory switch with the capacity to fine-tune CTNNB1/TCF signalling activity."

Second, the reviewer is also correct in noting that "Overall there is a lot of variability among the different experiments. The authors themselves say this on page 7 of the manuscript."

We initially suspected that these were pipetting errors, but after careful optimization of our experiments we suspect that this is actual, biological variation. We reported this variability to be transparent, but we now realize that it may have distracted from the main message of our manuscript, which is that TMEM98 binds and inhibits FRAT2.

In our revised manuscript, we have modified Figure 4 and the corresponding main text to

i\) properly illustrate the inherent spread in our data, ii) allow proper quantification of the results and iii) perform statistical testing:

\- We have removed the data in which we compare the effects of TMEM98 overexpression on FRAT1 and FRAT2 protein levels, so as not to confuse the reader or dilute our main message (which focuses on FRAT2). The text has been modified accordingly. The discussion (revised manuscript, page 21, lines 444-446) now reads: "TMEM98 also binds and inhibits FRAT1, but whether TMEM98 affects the biological activity of both homologues to the same extent remains to be determined."

\- We have included additional Western blots (for a total of 9 independent experiments) to quantify the effects of TMEM98 overexpression on FRAT2 protein levels (new Figure 4A, which now also includes statistical testing). The corresponding text (revised manuscript, page 15, lines 305-307) now reads: "Quantitative Western blot analysis revealed a variable, but consistent reduction in FRAT2 protein levels in the presence of full length TMEM98 (Fig 4A,B and S7A-C Fig)."

\- Some of the Western blots that were used in the first version of our manuscript (including those for the original Figure 4A and Supplementary Figure 5 and Supplementary Figure 7) may have been overexposed (as a result of using ECL detection and manual exposure of X-Ray film), thus preventing accurate/meaningful quantification. We have replaced these Western blots with new, non-saturated Western blots from new experiments using fluorescent antibodies and LICOR detection (new Supplementary Figure 7A-C). Although the corresponding results section (revised manuscript, page 15-16, lines 301-324), has been rewritten to focus on the TMEM98 mediated reduction of FRAT protein levels we want to stress that none of the changes we have made changes our original message or interpretation of the data.

We believe that as a result of these changes the flow of our story has improved and more speculative (e.g. the negative feedback loop model) and potentially confusing aspects (e.g. inherent variability) have been moved to the discussion and supplementary data.

8\) Statistics should be done to test the significance of the TOPFLASH reporter assays shown in Fig 4E and F. There is a great deal of overlap in the pink box (just TMEM98 RNAi) and the blue and green boxes (TMEM98 RNAi along with myc-FRAT1 or myc-FRAT2).

We have performed statistical testing for Figures 3-5 as requested and have updated the figures, figure legends and materials and methods accordingly. As can be seen in Figure 4E-F, only the increase in FRAT1 induced TOPFLASH reporter activity is statistically significant. We suspect that this is due to the fact that FRAT1 is a more potent activator of CTNNB1/TCF signaling than FRAT2 to begin with (see van Amerongen et al., 2004, JBC and van Amerongen et al., 2010, Oncogene), which allows for a larger dynamic range.

9\) In Supplementary Fig 7B and C the amount of TMEM98-FLAG is kept constant and the amounts of myc-FRAT1 and myc-FRAT2 are increased. The authors conclude that increased myc-FRAT2 increased TMEM98-FLAG levels but to me the signal from lane 1 (TMEM98-FLAG alone) looks extremely similar to the signal in 3 out of 4 of the lanes where increasing amounts of myc-FRAT2 were transfected. It is difficult to reach a convincing conclusion as to the effect of these two proteins on each other's stability.

Once again, we thank the reviewer for their careful consideration of our data and we agree that it is difficult to reach a convincing conclusion as to the effect of TMEM98 and FRAT2 on each other's stability. As detailed in our response to point 7) above, we have moved this more speculative aspect to the discussion and we have rewritten the results section to improve the flow and not distract from our main message.

10\) What do the yellow and blue arrowheads indicate in Fig. 6?

We apologize for not including this in the figure legend.

Yellow arrowheads indicate co-localization, whereas blue arrowheads indicate examples without co-localization. This has been corrected in the figure legend (now Figure 5 in the revised manuscript, page 19, lines 397-398).

11\) The reference list is duplicated.

We apologize for this error. This has been fixed in the revised manuscript.

Reviewer \#2

In this manuscript, van der Wal described that TMEM98 transmembrane protein interacts with FRAT2 and regulates its activity. The findings are interesting as they reveal a new layer of regulation of Wnt/b-catenin signaling. However, there are several major concerns that need to be addressed prior to publication.

We thank Reviewer \#2 for their comments and constructive feedback. We are confident that we have addressed all of their concerns in the revised version of our manuscript. Below, we will address all of their points in more detail.

1\. Figure 1：The binding between TMEM98 and FRAT2 appears to be very weak, as judged by the ratio between the FRAT2 band to the background bands which are faint in aFLAG but extremely strong in a-myc staining. This should be explained and discussed.

The reviewer is correct in noting that not all of the FRAT2 protein pool is bound by TMEM98. We agree that this can be explained by low affinity binding. However, we also offer another explanation: If our model, depicted in new Figure 6A (formerly Figure 7A), is correct, then only a small portion of the FRAT2 protein pool can come into contact with TMEM98. Thus, we think our immunoprecipitation data lend further support for a model in which the only interaction between FRAT2 and TMEM98 can take place inside MVBs. This has now been included in the discussion (page 22-23, lines 482-483: "our immunoprecipitation experiments support the fact that only a small proportion of the total FRAT2 protein pool interacts with TMEM98 (Fig 1)."). We thank reviewer 2 for pointing out this fact.

2\. In consideration of the false positive signal in yeast-two-hybrid assay, the interaction between TMEM98-ΔN and FRAT2 is not shown and should be repeated by co-immunoprecipitation in the presence of the proteasome inhibitor MG132, including Fig S5. It is necessary to show the binding between TMEM98 and FRAT2-ΔN as well.

We have not been able to detect an interaction between TMEM98�N and FRAT2 or between TMEM98 and FRAT2�N in co-immunoprecipitation experiments. We suspect that this is at least in part due to the fact that both deletion mutants (TMEM98�N and FRAT2�N) are mislocalized. As an example, we provide Figure 2 for the reviewer below, which illustrates the tendency of FRAT2�N to accumulate in the nucleus (a nuclear export signal is known to reside in the FRAT N-terminus: Franca-Koh et al., 2002, JBC). A precise dissection of the interaction between TMEM98 and FRAT2 would thus require an entirely different experimental approach, and we argue that this is beyond the scope of the current manuscript.

However, we want to point out that we provide multiple lines of evidence that support a physical and functional interaction between TMEM98 and FRAT2, including co-immunoprecipitation of the full length proteins (Figure 1), the fact that TMEM98�N is stabilized when FRAT2 is co-expressed (Figure 1), and the effect of both TMEM98 overexpression and knockdown on FRAT1 and FRAT2 protein levels and activity (Figures 3 and 4).

3\. Figure 2: The data in Fig 2C showed that TMEM98-GFP signals were found to be closely associated with the nucleus in the absence of treatment, suggesting its presence in ER as well. In the presence of Brefeldin A, the signals were restricted to the Golgi, does Brefeldin A disturb the export from distal Golgi compartments to the cell surface (Miller SG, 1992), and does Brefeldin A inhibit protein transport from the Golgi to the ER? If so, these data should suggest that TMEM98 is transported from Golgi to the ER?

We suspect that the reviewer has perhaps misinterpreted Figure 2C and we apologize for any confusion we may have caused. As the legend indicates, the "0 minutes" timepoint in Figure 2C refers to the chase time after release from a 4-hour treatment with Brefeldin A (revised manuscript, page 10, lines 190-192: "Cells were treated with Brefeldin A for 4 hours to block forward trafficking through the Golgi, after which they were released. Cells were fixed at 0, 30, 60 and 180 minutes following release."). Thus, the "0 minutes" timepoint does not reflect the absence of treatment, but the result of 4 hours of treatment with Brefeldin A. The reviewer is correct in noting that at this point, most of the TMEM98 signal is indeed restricted to the ER. This is in agreement with previous reports demonstrating a role for TMEM98 in this compartment (Huang et al., 2018, J Neuroscience). After a longer chase (60 minutes and longer after release from the Brefeldin A treatment) TMEM98 again traffics to the Golgi and the cell surface (see arrowheads in the 180 minute chase panel).

The extracellular location of TMEM98 C-terminus in Fig 2A was not well verified . Other methods should be performed to substantiate the subcellular localization of TMEM98, such as using the technique defined in (Lorenz H, 2006).

We thank the reviewer for suggesting that we perform a fluorescence protease protection (FPP) assay. We have considered this option to determine the orientation of TMEM98 in the plasma membrane. However, it would require us to also tag TMEM98 on the N-terminus and this is not possible due the presence of the N-terminal signal peptide and membrane anchor, which results in improper targeting and localization (as also shown in Supplementary Figure 3). This is one of the reasons why we chose to perform the FACS experiment depicted in Figure 2 instead. To our opinion, this experiment provides sufficient evidence that the C-terminus is located on the outside of the cell, confirming the experiments of Fu et al. (Fu et al., 2015, J Interferon Cytokine Res).

And, the TMEM98ΔN-AcGFP was invisible (or the weak signal appeared as blue?)

in Fig 2D.

A similar point was raised by Reviewer \#1. We include the image below for the reviewers, which also contains the negative control sample for the experiment depicted in Figure 2D. In the image below, we have enhanced the contrast and brightness such that the untransfected control cells (3rd panel) are just barely visible. Thus, the signal for TMEM98�N (2nd panel, as depicted in Figure 2D) is indeed low signal.

When the contrast and brightness of the TMEM98�N transfected cells are adjusted further (4th panel, 'boosted'), the untransfected cells in the well also become visible. In our revision, we have indicated the position of some of these cells with an asterisk in Figure 2D (see also figure legend, revised manuscript, page 10 lines 195-200). In addition, we have changed the LUT for Figures 2C-E for better contrast/visualization. Thus, we hope that the reviewer agrees that the cells transfected with TMEM98�N are indeed expressing low levels of the deletion mutant, which is in agreement with our Western blots result presented in Figure 1.

4\. Figure 2H: it is mentioned in methods that cells were treated with trypsin in FACS analysis. However, trypsin will remove the extracellular C-terminus of TMEM98-Flag. Did this affect the results?

We thank the reviewer for pointing this out. We cannot exclude that indeed some signal may have been lost due to cleavage by trypsin. In fact, we believe that this might explain why less than 100% of the cell population shows up as positive in the extracellular staining. We have included a remark to this effect in the materials and methods section (revised manuscript, page 32, lines 694-696: "Note that we cannot exclude that trypsinization may have resulted in partial cleavage of the FLAG-tagged C-terminus of TMEM98, which may have resulted in an underestimation of the signal."). However, we stress that this does not affect our main conclusion, which is that the C-terminus of TMEM98 is on the outside of the cell.

5\. Figure 3: since FRAT1 is a more potent activator of CTNNB1/TCF signaling than FRAT2 showed in Fig 3B, is it better to test the inhibition of FRAT1 activities in the presence of TMEM98 in Fig 3A?

We have performed our most elaborate set of experiments with FRAT2, given that this is how we initially identified TMEM98. We do find that FRAT1 also binds to TMEM98 (Supplementary Figure 5) and indeed, knockdown of TMEM98 increases FRAT1 mediated CTNNB1/TCF signaling (Figure 3). Thus, we propose that TMEM98 biologically interacts with both FRAT homologues. However, it is beyond the scope of the current study to investigate how similar and/or different the activities of TMEM98 towards FRAT1 and FRAT2 are.

We have removed the data in which we compare the effects of TMEM98 overexpression on FRAT1 and FRAT2 protein levels, so as not to confuse the reader or dilute our main message (which focuses on FRAT2). The text has been modified accordingly. This is also mentioned in the discussion (revised manuscript, page 21, lines 444-446): "TMEM98 also binds and inhibits FRAT1, but whether TMEM98 affects the biological activity of both homologues to the same extent remains to be determined."

Meanwhile, the conclusion is not convincing that TMEM98 consistently reduced the level of CTNNB1/TCF signaling in a dose-dependent manner according to Fig 3A (maybe due to the non-linear increase in TMEM98 protein levels).

We thank the reviewer for pointing this out. A similar point was raised by Reviewer \#1. Given that we only had two data points for this particular condition (i.e. the highest amount of Tmem98), this precludes meaningful statistical testing. Therefore, we have removed this condition from Figure 3A. We have modified the text so as not to overinterpret our data and have removed all instances of "dose-dependent" inhibition. Page 13, lines 263-264 now reads: "Co-transfection experiments showed that TMEM98 reduced the level of CTNNB1/TCF signalling induced by FRAT2 (Fig 3A)."

In our revised manuscript, we have modified Figure 4 and the corresponding main text to

i\) properly illustrate the inherent spread in our data, ii) allow proper quantification of the results and iii) perform statistical testing.

We have included additional Western blots (for a total of 9 independent experiments) to quantify the effects of TMEM98 overexpression on FRAT2 protein levels (new Figure 4A, which now also includes statistical testing). The corresponding text (revised manuscript, page 15, lines 305-307) now reads: "Quantitative Western blot analysis revealed a variable, but consistent reduction in FRAT2 protein levels in the presence of full length TMEM98 (Fig 4A,B and S7A-C Fig)."

Some of the Western blots that were used in the first version of our manuscript (including those for the original Figure 4A and Supplementary Figure 5 and Supplementary Figure 7) may have been overexposed (as a result of using ECL detection and manual exposure of X-Ray film), thus preventing accurate/meaningful quantification. We have replaced these Western blots with new, non-saturated Western blots from new experiments using fluorescent antibodies and LICOR detection (new Supplementary Figure 7A-C). Although the corresponding results section (revised manuscript, page 15-16, lines 301-324), has been rewritten to focus on the TMEM98 mediated reduction of FRAT protein levels we want to stress that none of the changes we have made changes our original message or interpretation of the data.

Did the level of phosphorylated β-catenin proteins change when transfected with TMEM98 and FRAT1/2?

Since TMEM98 reduces FRAT2 protein levels, it is expected that the levels of non-phosphorylated or active beta-catenin indeed change accordingly. However, this is likely to be a secondary effect, due to the change if FRAT2 levels and therefore we have not investigated this further.

6\. As TMEM98-AcGFP protein does not inhibit FRAT2 activity to the same extent as TMEM98-FLAG and TMEM98-mCherry, it may not be suitable for subcellular tracing TMEM98 proteins in Fig 2 and Fig 6.

Cranfill et al. reported the tendency of AcGFP to dimerize (Cranfill et al., 2016, Nature Methods), which is why we re-cloned our existing constructs into sGFP2 and mTq2 fusion proteins for our co-localization studies as a pre-caution. However, there is no reason to assume that an AcGFP fusion protein would result in major differences in trafficking at low levels of protein expression. In support of this, the plasma membrane and Golgi localization of TMEM98-AcGFP are confirmed by our results with TMEM98-sGFP2 (Figure 2A), as are other subcellular localization patterns in Figure 5 (formerly Figure 6), which were confirmed with co-localization of TMEM98-sGFP2 and/or TMEM98-mTq2 with Rab-fusion proteins (including Rab5, which supports our results for EEA1, data not shown).

7\. If the model in Fig 7B is correct, we would expect that the region between two transmembrane domains would interact with FRAT. Is this true?

The reviewer is correct that this is indeed our hypothesis. However, as we also point out, this would be hard to reconcile with some of the topology findings by Fu et al. (2015). At this point, both of our models are speculative. Future studies would be needed to determine the exact FRAT/TMEM98 binding interface. We have rewritten the discussion around Figure 6 (formerly Figure 7) to stress this point (revised manuscript, pages 21-23, lines 448-493).
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TMEM98 is a negative regulator of FRAT mediated Wnt/β-catenin signalling

PLOS ONE

Dear dr. van Amerongen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Both reviewers agree that the manuscript is considerably improved. However there remain some concerns that need to be addressed. Please ensure that all the statistics are complete and all figure legends are included in the manuscript.  Also, issues related to markers for immunoblots and the signal strength of plasma membrane labeling also need to be addressed.

We would appreciate receiving your revised manuscript by Jan 26 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Koval

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The paper is much improved. I just have a few minor comments to make.

Size markers are still not shown for all the Westerns, for example Fig 1B.

The authors say "In our revised manuscript, we have changed the LUT for Figures 2C-E to improve the contrast/visualization. We think that as a result, the plasma membrane signal (indicated by arrowheads) is now better visible and we hope the reviewer agrees." To me the signal at the cell periphery is still quite faint.

In figure 3B please show the P value for the luciferase activity of myc-FRAT2 with and without TMEM98-FLAG.

Please show the P value for the luciferase activity of myc-FRAT2 with and without TMEM98 RNAi \#3 in Fig 4E. I am not convinced Fig 4F adds anything. Is it just a way of showing the data in Fig 4E in a different way?

Apologies but I could not find the figure legends for the supplementary figures in the revised submission.

Reviewer \#2: The reviewers have adequately addressed my questions and concerns, and explained why some experiments can not be done at this stage.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227435.r004

Author response to Decision Letter 1

16 Dec 2019

Please see our official cover letter for a direct response to the points highlighted by the editor. Our response to the reviewers is also attached as a separate rebuttal, and pasted below:

We thank both reviewers for assessing the revised version of our manuscript. Below we want to take the opportunity to address the remaining comments of Reviewer \#1.

Reviewer \#1:

The paper is much improved. I just have a few minor comments to make.

Size markers are still not shown for all the Westerns, for example Fig 1B.

As shown in Figure 1, we have used the heavy chain (\~50 kDa) and light chain (\~25 kDa) bands from the antibodies used for the immunoprecipitation experiments as size markers (the same holds for Figure S5). Given that we had 12 samples to run for these pull downs on a 12-slot gel, this precluded the inclusion of a protein size marker. Therefore, we gave preference to running the lysates and the pull downs on a single gel over the inclusion of a separate marker.

As shown in the original data deposited at DOI 10.17605/OSF.IO/EF74W, these Western blots are clean and the heavy and light chain can be used reliably to get an impression of protein size distribution on the blot.

Please note that the panel on the left comes from the same gel as the panel on the right (only the order has been inversed, to depict the total lysates on the left and the pull downs on the right). These markers thus refer to both panels (direct lysates and pull downs).

We have double-checked all other Western blots in the main figures and supplementary figures, and all of them now have size markers. We apologize for not catching all of these omissions in our previous resubmission.

Please note that the sole exception is the experiment depicted in Figure 4C/D, where we unfortunately forgot to copy the size markers onto the film after developing the Western blot (ECL detection). Here, we ask the reviewer to please also assess all of the original data deposited at DOI 10.17605/OSF.IO/EF74W, which shows that myc-Frat1/2 and Tmem98-FLAG reliably run at the expected sizes in all experiments (i.e. between 25 kDa and 35 kDa).

The authors say "In our revised manuscript, we have changed the LUT for Figures 2C-E to improve the contrast/visualization. We think that as a result, the plasma membrane signal (indicated by arrowheads) is now better visible and we hope the reviewer agrees." To me the signal at the cell periphery is still quite faint.

We agree with this reviewer that the signal in the plasma membrane is "still quite faint" for the images depicted in Figure 2C-E. However, we want to emphasize that our message is not that TMEM98 is predominantly located in the plasma membrane, but that it is present in the plasma membrane at all.

As described on pages 8-9, TMEM98 is both predicted to be secreted as well as to be a transmembrane protein. Our experiments (mainly Figure 2A and Figure 2H) support that at least part of the TMEM98 pool resides in the plasma membrane, which we believe is an important confirmation of the resident location of TMEM98. Figure 2C supports this conclusion, since it shows that after being trapped in the ER following Brefeldin A treatment, part of the TMEM98 pool again reaches the plasma membrane 3 hours after release (arrowheads in Figure 2C).

To show the reviewer additional examples, we provide the images below. These also show TMEM98 returning to the plasma membrane 2 hours (top left) and 3 hours (following 3 images) after release from Brefeldin A treatment. Please note that the image depicted in 2C is also shown in the images below (bottom right).

2 hours after release. Note plasma membrane signal at the cell-cell border.

3 hours after release. Note the subtle outline of the plasma membrane.

3 hours after release. Note the subtle outline of the plasma membrane.

3 hours after release (same as image 2C). Note the subtle outline of the plasma membrane and the visibility of the distal cell membrane protrusions.

The grey scale enhances the contrast, but the reviewer is right: the signal in the plasma membrane is subtle. As we already indicated in our previous rebuttal: We observed the clearest plasma membrane staining in living, unfixed HeLa cells (hence the example in Figure 2A). Please note that Figure 2C was made using PFA fixed cells, which in our hands reduced the intensity of the plasma membrane signal. The plasma membrane signal is also faint compared to other subcellular structures (including the Golgi, see also examples provided above), particularly in fixed cells (as e.g. Figure 2C). In these images, we set our PMT/gain so as not to oversaturate the most intense signal (Golgi/ER), causing the plasma membrane signal to be relatively low. Please note that all of these subtleties are indicated in the Legend for Figure 2.

Taken all of this together, we stand by our conclusion as stated in the manuscript on pages 8-9: "A TMEM98-GFP fusion protein indeed localizes to the plasma membrane (Fig 2A), in addition to showing more prominent localization to the Golgi and intracellular vesicles (Fig 2A-B)."

In figure 3B please show the P value for the luciferase activity of myc-FRAT2 with and without TMEM98-FLAG.

We analyzed our data with Prism, using a one-way ANOVA and Tukey's multiple comparisons test (comparing every condition to every other condition). In this analysis, neither the difference between vector and myc-Frat2 alone (first condition vs. fifth condition), nor the difference between myc-Frat2 alone and myc-Frat2 + TMEM98-FLAG is statistically significant (i.e. the P value is \>0.05). One explanation is the large intrinsic difference in the ability of Frat1 and Frat2 to induce TOPFLASH luciferase reporter activity, with Frat2 being a less potent activator of CTNNB1/TCF signaling (van Amerongen et al., Journal of Biological Chemistry, 2004 and van Amerongen et al., Oncogene, 2010).

We chose to show only significant comparisons in the figure (as stated in the figure legend), which is why this P-value is not shown/depicted. The figures would get really cluttered if all non-significant comparisons are also included.

We have modified the last sentence of the figure legend (page 15), which now states "Only statistically significant differences (one-way ANOVA, Tukey's multiple comparisons test) are indicated with asterisks".

Please show the P value for the luciferase activity of myc-FRAT2 with and without TMEM98 RNAi \#3 in Fig 4E.

As above:

When analyzed using a one-way ANOVA and Tukey's multiple comparisons test (comparing every condition to every other condition), neither the difference between vector and myc-Frat2 alone (first condition vs. fifth condition), nor the difference between myc-Frat2 alone and myc-Frat2 + RNAi \#3 is statistically significant (i.e. the P value is \>0.05). We chose to show only significant comparisons in the figure (as stated in the figure legend), which is why this P-value is not shown/depicted. The figures would get really cluttered if all non-significant comparisons are also included. We have now modified the figure to include all significant comparisons (also Frat1 compared to vector, for instance) and we have changed the last sentence of the figure legend (page 16), which now states "Only statistically significant differences (one-way ANOVA, Tukey's multiple comparisons test) are indicated with asterisks".

I am not convinced Fig 4F adds anything. Is it just a way of showing the data in Fig 4E in a different way?

The reviewer is correct, this is a different representation of the same data, as stated in the figure legend on page 16.

Apologies but I could not find the figure legends for the supplementary figures in the revised submission.

Please note that the supplementary figure legends should have been included as a separate file (Supplementary Files.docx / Supplementary Files.pdf) with our last submission, since it was our impression that they should not be included with the main manuscript as per PLOS ONE manuscript preparation guidelines.

This time they have again been uploaded as a separate file, again named Supplementary Files.docx / Supplementary Files.pdf

Reviewer \#2:

The reviewers have adequately addressed my questions and concerns, and explained why some experiments can not be done at this stage.

We thank Reviewer \#2 for their time and effort.
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Dear Dr. van Amerongen,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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